NOVEL BACTERIOPHAGE THAT LYSES ACINETOBACTER GENUS BACTERIA HAVING RESISTANCE TO ANTIBIOTICS

Abstract

The present invention relates to a novel bacteriophage that lyses Acinetobacter genus bacteria, in particular, Acinetobacter genus bacteria having resistance to antibiotics. The bacteriophage of the present invention can be used in various fields, such as antibiotic composition, feed additive composition, feed, disinfectant, cleaning agent, and a composition for prevention or treatment of an infectious disease caused by Acinetobacter genus bacteria.

Claims

1. A bacteriophage that has a specific killing ability against Acinetobacter genus bacteria and belongs to the family Myoviridae.

2. The bacteriophage according to claim 1, wherein the Acinetobacter genus bacteria are at least one selected from the group consisting of Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Acinetobacter junii, Acinetobacter johnsonii, Acinetobacter lwoffii, Acinetobacter radioresistens, Acinetobacter ursingii, Acinetobacter schindleri, Acinetobacter parvus, Acinetobacter baylyi, Acinetobacter bouvetii, Acinetobacter towneri, Acinetobacter tandoii, Acinetobacter grimontii, Acinetobacter tjernbergiae, and Acinetobacter gerneri.

3. The bacteriophage according to claim 1, wherein the Acinetobacter genus bacteria are Acinetobacter baumannii.

4. The bacteriophage according to claim 1, wherein the Acinetobacter genus bacteria are antibiotic-resistant bacteria.

5. The bacteriophage according to claim 4, wherein the antibiotics are carbapenem-based antibiotics.

6. The bacteriophage according to claim 4, wherein the antibiotics are at least one selected from the group consisting of amikacin, ampicillin, ampicillin-sulbactam, aztreonam, ciprofloxacin, ceftazidime, cefazolin, ertapenem, cefepime, cefoxitin, cefotaxime, gentamicin, levofloxacin, minocycline, imipenem, meropenem, piperacillin, piperacillin-tazobactam, cortrimoxa, and tigecycline.

7. The bacteriophage according to claim 1, wherein the bacteriophage is any one of a bacteriophage which is designated YMC14/01/P117_ABA_BP and has an accession number of KFCC11800P; a bacteriophage which is designated YMC16/12/R4637_ABA_BP and has an accession number of KFCC11801P; or a bacteriophage which is designated YMC16/01/R2016_ABA_BP and has an accession number of KFCC11803P.

8. The bacteriophage according to claim 1, wherein the bacteriophage includes a genome represented by SEQ ID NO: 1, 8, or 13.

9. The bacteriophage according to claim 1, wherein the bacteriophage includes any one protein of SEQ ID NOs: 2 to 4, 9, 10, and 14 to 16.

10. The bacteriophage according to claim 1, wherein the bacteriophage includes a genome represented by any one of SEQ ID NOs: 5 to 7, 11, 12, and 17 to 19.

11. A composition of antibiotics, disinfection or cleaning, comprising as an active ingredient: the bacteriophage according to claim 1.

12. A method for preventing or treating a disease caused by Acinetobacter genus bacteria, comprising: a step of administering, to an individual, the bacteriophage according to claim 1.

13. The method according to claim 12, wherein the disease caused by Acinetobacter genus bacteria is a disease selected from the group consisting of hepatitis C, hand-foot-and-mouth disease, gonorrhea, chlamydia, chancroid, genital herpes, condylomata acuminata, vancomycin-resistant Staphylococcus aureus infection, vancomycin-resistant Enterococci infection, methicillin-resistant Staphylococcus aureus infection, multi-drug-resistant Pseudomonas aeruginosa infection, multi-drug-resistant Acinetobacter baumannii infection, carbapenem-resistant Enterobacteriaceae infection, intestinal infection, acute respiratory infection, and Enterovirus infection.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0088] FIG. 1 illustrates a photograph, taken with an electron microscope, of the bacteriophage YMC14/01/P117_ABA_BP in Example 1 of the present invention.

[0089] FIG. 2 graphically illustrates results obtained by evaluating adsorption capacity of the bacteriophage YMC14/01/P117_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 1 of the present invention.

[0090] FIG. 3 illustrates a one-step growth curve of the lytic bacteriophage YMC14/01/P117_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 1 of the present invention.

[0091] FIG. 4 graphically illustrates ex vivo lytic ability of the bacteriophage YMC14/01/P117_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 1 of the present invention.

[0092] FIG. 5 graphically illustrates results obtained by subjecting Galleria mellonella larvae, which has been infected with Acinetobacter genus bacteria having resistance to antibiotics, to treatment with the bacteriophage YMC14/01/P117_ABA_BP, and then observing changes in survival of the Galleria mellonella larvae, in Example 1 of the present invention.

[0093] FIG. 6 graphically illustrates pH stability of the lytic bacteriophage YMC14/01/P117_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 1 of the present invention.

[0094] FIG. 7 graphically illustrates temperature stability of the lytic bacteriophage YMC14/01/P117_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 1 of the present invention.

[0095] FIG. 8 illustrates results obtained by whole-genome sequencing of the bacteriophage YMC14/01/P117_ABA_BP in Example 1 of the present invention.

[0096] FIG. 9 illustrates a photograph, taken with an electron microscope, of the bacteriophage YMC16/12/R4637_ABA_BP in Example 2 of the present invention.

[0097] FIG. 10 graphically illustrates results obtained by evaluating adsorption capacity of the bacteriophage YMC16/12/R4637_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 2 of the present invention.

[0098] FIG. 11 illustrates a one-step growth curve of the lytic bacteriophage YMC16/12/R4637_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 2 of the present invention.

[0099] FIG. 12 graphically illustrates results obtained by subjecting Galleria mellonella larvae, which has been infected with Acinetobacter genus bacteria having resistance to antibiotics, to treatment with the bacteriophage YMC16/12/R4637_ABA_BP, and then observing changes in survival of the Galleria mellonella larvae, in Example 2 of the present invention.

[0100] FIG. 13 graphically illustrates pH stability of the lytic bacteriophage YMC16/12/R4637_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 2 of the present invention.

[0101] FIG. 14 graphically illustrates temperature stability of the lytic bacteriophage YMC16/12/R4637_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 2 of the present invention.

[0102] FIG. 15 illustrates results obtained by whole-genome sequencing of the bacteriophage YMC16/12/R4637_ABA_BP in Example 2 of the present invention.

[0103] FIG. 16 illustrates a photograph, taken with an electron microscope, of the bacteriophage YMC16/01/R2016_ABA_BP in Example 3 of the present invention.

[0104] FIG. 17 graphically illustrates results obtained by evaluating adsorption capacity of the bacteriophage YMC16/01/R2016_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 3 of the present invention.

[0105] FIG. 18 illustrates a one-step growth curve of the lytic bacteriophage YMC16/01/R2016_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 3 of the present invention.

[0106] FIG. 19 graphically illustrates results obtained by subjecting Galleria mellonella larvae, which has been infected with Acinetobacter genus bacteria having resistance to antibiotics, to treatment with the bacteriophage YMC16/01/R2016_ABA_BP, and then observing changes in survival of the Galleria mellonella larvae, in Example 3 of the present invention.

[0107] FIG. 20 graphically illustrates pH stability of the lytic bacteriophage YMC16/01/R2016_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 3 of the present invention.

[0108] FIG. 21 graphically illustrates temperature stability of the lytic bacteriophage YMC16/01/R2016_ABA_BP against Acinetobacter genus bacteria having resistance to antibiotics in Example 3 of the present invention.

[0109] FIG. 22 illustrates results obtained by whole-genome sequencing of the bacteriophage YMC16/01/R2016_ABA_BP in Example 3 of the present invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0110] Hereinafter, the present invention will be described in detail by way of the following examples. However, the following examples are only illustrative of the present invention, and the scope of the present invention is not limited by the following examples.

EXAMPLES

[Example 1] Bacteriophage YMC14/01/P117 ABA_BP

[0111] 1. Isolation of Clinical Specimens and Selection of Antibiotic-Resistant Strains

[0112] As shown in Table 1 below, Acinetobacter baumannii strains were isolated from blood, clinical specimens, and the like obtained from the intensive care unit (ICU) of a university hospital, and cultured. Strain identification was performed using a kit such as ATB 32 GN system (bioMérieux, Marcy l'Etoile, France). Subsequently, for antibiotic susceptibility test, a CLSI disk diffusion test method, in which culture is performed overnight at 37° C. in outside air using Mueller-Hinton agar, was used; and for test antibiotics, amikacin, ampicillin-sulbactam, ceftazidime, ciprofloxacin, colistin, cefepime, cefotaxime, gentamicin, imipenem, levofloxacin, meropenem, minocycline, piperacillin, piperacillin-tazobactam, cortrimoxa, and tigecycline were used. The susceptibility results were read based on the Clinical and Laboratory Standards Institute (CLSI, 2016). Antibiotic resistance profiles of the collected Acinetobacter baumannii strains are shown in Table 2 below. In Table 2 below, S, I, and R are the results obtained by evaluating susceptibility to the antibacterial agents, in which ‘S’ means susceptible, ‘I’ means intermediate, and ‘R’ means resistant.

TABLE-US-00001 TABLE 1 Host strain Origin of sample Host strain Origin of sample YMC14/01/R130 Sputum (pneumonia) YMC14/01/R2429 Tracheal aspirate (pneumonia) YMC14/01/R160 Sputum (pneumonia) YMC14/01/P728 Decubitus ulcer YMC14/01/C29 Ascites (drainage) YMC14/01/R2572 Tracheal aspirate (pneumonia) YMC14/01/P31 Swab or drainage tube, YMC14/01/R2855 Sputum (pneumonia) abdomen YMC14/01/U313 Random urine YMC14/01/R2945 Sputum (pneumonia) YMC14/01/R198 Tracheal aspirate YMC14/01/P727 Swab or drainage tube, (pneumonia) abdomen YMC14/01/R324 Sputum (pneumonia) YMC14/01/R3129 Sputum (pneumonia) YMC14/01/R257 Sputum (pneumonia) YMC14/01/R3007 Sputum (pneumonia) YMC14/01/R270 Sputum (pneumonia) YMC14/01/R3317 Sputum (pneumonia) YMC14/01/P122 Swab or drainage tube, YMC14/01/R3474 Sputum (pneumonia) pelvis YMC14/01/P117 Decubitus ulcer YMC14/01/R3574 Tracheal tube tip YMC14/01/U318 Random urine YMC14/02/P47 Bile, PTBD YMC14/01/P212 YMC14/02/R542 Sputum (pneumonia) YMC14/01/R443 Sputum (pneumonia) YMC14/02/U1607 Random urine YMC14/01/R451 Tracheal aspirate YMC14/02/R1860 Sputum (pneumonia) (pneumonia) YMC14/01/R560 Sputum (pneumonia) YMC14/02/L18 Bronchoalveolar lavage YMC14/01/R617 Sputum (pneumonia) YMC14/02/R2417 Sputum (pneumonia) YMC14/01/R671 Tracheal aspirate YMC14/02/R2668 Sputum (pneumonia) (pneumonia) YMC14/01/R732 Sputum (pneumonia) YMC14/02/R2599 Tracheal aspirate (pneumonia) YMC14/01/R767 Sputum (pneumonia) YMC14/02/R2781 Tracheal aspirate (pneumonia) YMC14/01/L8 Bronchoalveolar lavage YMC14/02/R2758 Mouth YMC14/01/R905 Sputum (pneumonia) YMC14/02/R3106 Sputum (pneumonia) YMC14/01/R904 Sputum (pneumonia) YMC14/02/R3419 Sputum (pneumonia) YMC14/01/R941 Tracheal aspirate YMC14/03/R217 Sputum (pneumonia) (pneumonia) YMC14/01/R958 Sputum (pneumonia) YMC14/03/R122 Sputum (pneumonia) YMC14/01/P224 Swab or drainage tube, hip YMC14/03/R380 Tracheal aspirate (pneumonia) YMC14/01/R1006 Sputum (pneumonia) YMC14/03/R618 Sputum (pneumonia) YMC14/01/R921 Sputum (pneumonia) YMC14/03/L9 Bronchoalveolar lavage YMC14/01/R1659 Tracheal aspirate YMC14/03/P471 Swab or drainage tube, (pneumonia) hand YMC14/01/R1722 Tracheal aspirate YMC14/03/R2144 Sputum (pneumonia) (pneumonia) YMC14/01/R1752 Sputum (surveillance) YMC14/03/U4616 Random urine YMC14/01/R1199 Tracheal tube tip YMC14/04/R1080 Sputum (pneumonia) YMC14/01/R2036 YMC14/04/R1078 Sputum (pneumonia)

TABLE-US-00002 TABLE 2 Host Ampicillin- strain Amikacin sulbactam Ceftazidime Ciprofloxacin Colistin Cefepime Cefotaxime Gentamicin Imipenem YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R130 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R160 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R C29 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R P31 YMC14/01/ 6 R =2 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R U313 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R198 YMC14/01/ 6 R    8 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R324 YMC14/01/ 23 S  =32 R =64 R =4 R =0.5 S =64 R =64 R  =1 S =16 R R257 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R270 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S   32 R =64 R =16 R =16 R P122 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R P117 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R U318 YMC14/01/ P212 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R443 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R451 YMC14/01/ 8 R =32 R =64 R =4 R =0.5 S =64 R =64 R    2 S =16 R R560 YMC14/01/ 6 R =32 R   16 I =4 R =0.5 S =64 R =64 R =16 R =16 R R617 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R671 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R732 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R767 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R L8 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R905 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R904 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R941 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R958 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R P224 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R1006 YMC14/01/ 23 S    16 I =64 R =4 R =0.5 S   16 I =64 R    8 I =16 R R921 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R1659 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R1722 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R1752 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R1199 YMC14/01/ R2036 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2429 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R P728 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2572 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S   32 R =64 R =16 R =16 R R2855 YMC14/01/ 6 R    4 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2945 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R P727 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3129 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3007 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3317 YMC14/01/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3474 YMC14/01/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3574 YMC14/02/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R P47 YMC14/02/ R542 YMC14/02/ 20 S    16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R U1607 YMC14/02/ 27 S    16 I =64 R =4 R =0.5 S    8 S =64 R    8 I =16 R R1860 YMC14/02/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R L18 YMC14/02/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2417 YMC14/02/ 6 R    8 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2668 YMC14/02/ 20 S  =32 R =64 R =4 R =0.5 S =64 R =64 R    2 S =16 R R2599 YMC14/02/ 6 R =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2781 YMC14/02/ 6 R    8 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2758 YMC14/02/ 6 R    8 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3106 YMC14/02/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R3419 YMC14/03/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R217 YMC14/03/ 17 S  =32 R =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R122 YMC14/03/ 6 R    8 S =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R380 YMC14/03/ 21 S     8 S =64 R =4 R =0.5 S =64 R =64 R    2 S =16 R R618 YMC14/03/ 20 S    16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R L9 YMC14/03/ 22 S     8 S =64 R =4 R =0.5 S =64 R =64 R    2 S =16 R P471 YMC14/03/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R R2144 YMC14/03/ 6 R   16 I =64 R =4 R =0.5 S =64 R =64 R =16 R =16 R U4616 YMC14/04/ 20 S     4 S =64 R =4 R =0.5 S   32 R =64 R    2 S =16 R R1080 YMC14/04/ 20 S  =32 R =64 R =4 R =0.5 S =64 R =64 R    2 S =16 R R1078 Host Piperacillin- strain Levofloxacin Meropenem Minocycline Piperacillin tazobactam Cortrimoxa Tigecycline YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R130 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 1 S R160 YMC14/01/ =8 R =16 R   4 S =128 R =128 R =320 R 1 S C29 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S P31 YMC14/01/ =8 R =16 R   2 S =128 R =128 R =320 R =8 R   U313 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S R198 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R324 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S R257 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R270 YMC14/01/   4 I =16 R   2 S =128 R =128 R  =20 S 1 S P122 YMC14/01/   4 I =16 R =1 S =128 R =128 R   160 R 2 S P117 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S U318 YMC14/01/ P212 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 1 S R443 YMC14/01/ =8 R =16 R =16 R  =128 R =128 R =320 R 2 S R451 YMC14/01/ =8 R =16 R =16 R  =128 R =128 R   160 R =8 R   R560 YMC14/01/ =8 R =16 R =16 R  =128 R =128 R =320 R 2 S R617 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S R671 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R732 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R767 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R =0.5 S    L8 YMC14/01/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S R905 YMC14/01/ =8 R =16 R   8 I =128 R =128 R  =20 S 2 S R904 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R941 YMC14/01/ =8 R =16 R   4 S =128 R =128 R =320 R =8 R   R958 YMC14/01/ =8 R =16 R   2 S =128 R =128 R =320 R 4 I P224 YMC14/01/ =8 R =16 R   2 S =128 R =128 R =320 R 2 S R1006 YMC14/01/ =8 R =16 R   2 S =128 R =128 R    40 S 2 S R921 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R1659 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R1722 YMC14/01/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S R1752 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R1199 YMC14/01/ R2036 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R2429 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S P728 YMC14/01/ =8 R =16 R   2 S =128 R =128 R =320 R 4 I R2572 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R 1 S R2855 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R2945 YMC14/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   P727 YMC14/01/ =8 R =16 R =1 S =128 R =128 R  =20 S 4 I R3129 YMC14/01/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S R3007 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R3317 YMC14/01/   4 I =16 R =1 S =128 R =128 R   160 R 1 S R3474 YMC14/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R3574 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R 4 I P47 YMC14/02/ R542 YMC14/02/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S U1607 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R 4 I R1860 YMC14/02/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S L18 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2417 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R2668 YMC14/02/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S R2599 YMC14/02/ =8 R =16 R =1 S =128 R =128 R 160 R 2 S R2781 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R2758 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R3106 YMC14/02/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R3419 YMC14/03/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R217 YMC14/03/ =8 R =16 R =1 S =128 R =128 R  =20 S =8 R   R122 YMC14/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R380 YMC14/03/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S R618 YMC14/03/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S L9 YMC14/03/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S P471 YMC14/03/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R2144 YMC14/03/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S U4616 YMC14/04/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S R1080 YMC14/04/ =8 R =16 R =1 S =128 R =128 R  =20 S 1 S R1078

[0113] As shown in Table 2, the collected 66 Acinetobacter baumannii strains were found to be multi-drug-resistant strains having resistance to various antibiotics.

[0114] 2. Collection of Bacteriophage Specimens

[0115] 2-1. Collection of Specimens to Construct Phage Bank

[0116] Raw water was obtained by causing sewage to pass through a first sedimentation tank at the sewage treatment facility of the Severance Hospital (Korea), and then removing suspended substances and sediments therefrom. The sewage was limited to sewage that was present at a preliminary stage of a chemical treatment facility. To the collected sample was added 58 g of sodium chloride per L. Then, centrifugation was performed at 10,000 g for 10 minutes and filtration was performed through a 220 nm Millipore filter. To the obtained filtrate was added polyethylene glycol (PEG, molecular weight of 8000) at 10% w/v, and the resultant was stored refrigerated at 4° C. for 12 hours. The filtrate stored refrigerated for 12 hours was centrifuged at 12,000 g for 20 minutes, and the precipitate was resuspended in phage dilution buffer (SM buffer). To the resuspension was then added the same amount of chloroform, and the resultant was stored frozen. This was repeated three times to collect 300 mL of bacteriophage suspension.

[0117] 2-2. Selection of Lytic Phage and Measurement of Lysis Titer

[0118] Separation and purification of lytic phage were performed by a spot test method (Mazzocco A et al. In Bacteriophages, Clokie and Kropinski AM, eds. Humana Press. 2009). The obtained strains were inoculated on MacConkey Agar medium and then cultured overnight at 35° C. in outside air. After the culture, strains susceptible to phage were selected by observing formation of clear plaque. The susceptible strains were inoculated on MacConkey Agar medium and cultured at 35° C. for 12 hours. A suspension of each strain was prepared in a 1 ml saline tube with a turbidity of 0.5 McFarland, and mixed with H top agar (3 ml), 100 μl of sensitive bacteria, and a phage solution (each of 1 μl, 10 μl, and 50 μl). The mixture was applied to LB agar, and then cultured at 35° C. for 12 hours. Plaque was observed, and then the plaque was collected with a Pasteur pipette. The collected plaque was diluted in SM buffer solution, and repeatedly purified three times using the susceptible strain suspension again. The thus obtained pure bacteriophage, YMC14/01/P117_ABA_BP, was diluted in SM buffer solution, and repeatedly purified three times using the susceptible strain suspension again. The thus obtained pure bacteriophage, YMC14/01/P117_ABA_BP, was diluted in SM buffer solution and stored.

[0119] Each of the 32 antibiotic-resistant Acinetobacter baumannii strains identified in item no. 1. above was inoculated on MacConkey Agar medium and cultured. Then, the bacteriophage YMC14/01/P117_ABA_BP, which had been purified by the above process, was inoculated in an amount of 5 μl into each smeared resistant strain. Then, plaque formation was checked and a titer range thereof was checked. The lysis of each strain is shown in Table 3 below. In Table 3 below, an evaluation result of plaque activity against the collected strains is indicated by + and −, in which ‘+’ means clear plaque and ‘-’ means that lysis has not occurred.

TABLE-US-00003 TABLE 3 Host strain Lysis Host strain Lysis YMC14/01/R130 + YMC14/01/R3317 + YMC14/01/P31 + YMC14/01/R3474 + YMC14/01/U313 ++ YMC14/01/R3574 + YMC14/01/R324 + YMC14/02/P47 + YMC14/01/R270 + YMC14/02/R542 + YMC14/01/P117 + YMC14/02/U1607 + YMC14/01/R732 + YMC14/02/R1860 + YMC14/01/R767 + YMC14/02/L18 + YMC14/01/R904 + YMC14/02/R2417 + YMC14/01/R941 + YMC14/02/R2668 + YMC14/01/P224 + YMC14/02/R2599 + YMC14/01/R1006 + YMC14/02/R2781 + YMC14/01/R921 + YMC14/02/R2758 + YMC14/01/R1659 + YMC14/02/R3106 + YMC14/01/R1722 + YMC14/02/R3419 + YMC14/01/R1752 + YMC14/03/R217 + YMC14/01/R1199 + YMC14/03/R122 + YMC14/01/R2036 ++ YMC14/03/R380 + YMC14/01/R2429 + YMC14/03/R618 + YMC14/01/P728 + YMC14/03/L9 + YMC14/01/R2572 + YMC14/03/P471 + YMC14/01/R2855 + YMC14/03/R2144 + YMC14/01/R2945 + YMC14/03/U4616 + YMC14/01/P727 + YMC14/04/R1080 + YMC14/01/R3129 + YMC14/04/R1078 + YMC14/01/R3007 +

[0120] As shown in Table 3, it was found that the bacteriophage YMC14/01/P117_ABA_BP according to the present invention lyses antibiotic-resistant Acinetobacter baumannii strains.

[0121] 3. Electron Microscopic Analysis of Lytic Bacteriophage Against Antibiotic-Resistant Acinetobacter baumannii Strains

[0122] The bacteriophage YMC14/01/P117_ABA_BP purified by the method of item no. 2. above was inoculated and cultured in culture medium (20 ml of LB medium) for susceptible strains, and then filtered through a 220 nm Millipore filter. To the supernatant was added polyethylene glycol (MW 8,000) in an amount of 10% (w/v), and then the resultant was stored refrigerated overnight. Subsequently, centrifugation was performed for 20 minutes at 12,000 g, and then a shape of the bacteriophage YMC14/01/P117_ABA_BP was analyzed using an energy-filtering transmission electron microscope. The result is illustrated in FIG. 1.

[0123] As illustrated in FIG. 1, in a case where classification is made on a shape basis, the bacteriophage YMC14/01/P117_ABA_BP according to the present invention was classified as belonging to the family Myoviridae that has a long tail with a hexagonal head.

[0124] 4. Analysis of Adsorption Capacity and One-Step Growth Curve of Bacteriophage

[0125] The antibiotic-resistant Acinetobacter baumannii strain was cultured to an OD value of 0.5. To the Acinetobacter baumannii strain was then added the bacteriophage YMC14/01/P117_ABA_BP purified in item no. 2. above at an MOI of 0.001 and culture was performed at room temperature. Then, sample was collected 1 ml each at 1, 2, 3, 4, and 5 minutes, diluted in LB medium, and then adsorption capacity of the bacteriophage was evaluated through plaque analysis. The results are illustrated in FIG. 2.

[0126] In addition, the antibiotic-resistant Acinetobacter baumannii strain was cultured to an OD value of 0.3, and then centrifuged at 7,000 g for 5 minutes at 4° C., to precipitate the cells. Then, the cells were diluted in 0.5 ml of LB medium. To the dilute was added the bacteriophage YMC14/01/P117_ABA_BP purified in item no. 2. above at an MOI of 0.001 (titer of 108 pfu/cell), and culture was performed at 37° C. for 5 minutes. The cultured mixed sample was centrifuged at 13,000 g for 1 minute to obtain a pellet. The obtained pellet was diluted in 10 ml of LB medium and cultured at 37° C. Samples were collected every 10 minutes during the culture, and a one-step growth curve of the bacteriophage was evaluated through plaque analysis. The results are illustrated in FIG. 3.

[0127] As illustrated in FIG. 2, about 99% of the bacteriophage YMC14/01/P117_ABA_BP was adsorbed to the Acinetobacter baumannii strain within 4 minutes after inoculation of the bacteriophage.

[0128] In addition, as illustrated in FIG. 3, the one-step growth curve showed a high burst size of approximately 38.08 PFU/infected cells.

[0129] From the above results, it can be seen that the bacteriophage YMC14/01/P117_ABA_BP according to the present invention can be adsorbed in a relatively short time to an antibiotic-resistant Acinetobacter baumannii strain and can show a high burst size of 38.08 PFU/infected cells, indicating that this bacteriophage exerts a lytic effect on an antibiotic-resistant strain.

[0130] 5. Verification of Ex Vivo Lysis Ability of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0131] The antibiotic-resistant Acinetobacter baumannii strain at 1×10.sup.9 CFU/ml was treated with the prepared bacteriophage YMC14/01/P117_ABA_BP in an amount of 1×10.sup.8 CFU/ml (MOT: 0.1), 1×10.sup.9 PFU/ml (MOT: 1), or 1×10.sup.10 PFU/ml (MOT: 10), respectively, and OD values (wavelength of 600 nm) were measured over time. Here, as a negative control, treatment with PBS+SM buffer was performed. The values are illustrated in FIG. 4.

[0132] As illustrated in FIG. 4, in a case where the Acinetobacter baumannii strain is treated with the bacteriophage YMC14/01/P117_ABA_BP, an OD value decreased, in which the OD value further decreased as an MOI value increased, and in particular, the highest lysis ability was observed when the MOI was 10.

[0133] From the above results, it can be seen that the bacteriophage YMC14/01/P117_ABA_BP according to the present invention has lytic properties against an antibiotic-resistant Acinetobacter baumannii strain.

[0134] 6. Verification of In Vivo Lysis Ability of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0135] 200 third- to fourth-instar Galleria mellonella larvae were prepared, and then divided into groups, each containing 10 larvae. Each larva was injected through its proleg with a carbapenem-resistant Acinetobacter baumannii strain at a minimum lethal dose (MLD), and then subjected to mixed inoculation with the bacteriophage YMC14/01/P117_ABA_BP purified in item no. 2. above at an MOI of 10 or an MOI of 100. Then, survival of the larvae was checked every 12 or 24 hours until 72 hours, and the results are illustrated in FIG. 5.

[0136] As illustrated in FIG. 5, it was found that in a case where the larvae injected with the carbapenem-resistant Acinetobacter baumannii strain are treated with the bacteriophage YMC14/01/P117_ABA_BP according to the present invention, survival of the larvae increases, in which the survival of the larvae further increases as the MOI value increases. In addition, it was found that even in a case where the larvae are injected with only the bacteriophage YMC14/01/P117_ABA_BP without injection of the carbapenem-resistant Acinetobacter baumannii strain, no toxicity is seen when survival thereof is compared with that of a healthy control group.

[0137] From the above results, it can be seen that the bacteriophage YMC14/01/P117_ABA_BP according to the present invention also has lytic properties in vivo against an antibiotic-resistant Acinetobacter baumannii strain, and thus can effectively prevent, ameliorate, or treat an infectious disease caused by the Acinetobacter baumannii strain.

[0138] 7. Evaluation of Stability of Bacteriophage Against Antibiotic-Resistant Acinetobacter baumannii Strain

[0139] It was identified whether the bacteriophage YMC14/01/P117_ABA_BP according to the present invention maintains stability without being destroyed under alkaline and temperature conditions.

[0140] 1 μl of the bacteriophage YMC14/01/P117_ABA_BP purified by the method of item no. 2 above was added to 40 μl of SM buffer, which had been adjusted to a pH of 4, 5, 6, 7, 8, 9, or 10, and then incubated at 37° C. for 1 hour. Then, plaque analysis was performed with the antibiotic-resistant Acinetobacter baumannii bacteria using the method of item no. 4 above. The results are illustrated in FIG. 6.

[0141] In addition, during 1-hour incubation of the bacteriophage YMC14/01/P117_ABA_BP solution at 4° C., 37° C., 50° C., 60° C., and 70° C., respectively, each sample was collected every 10 minutes and plaque analysis was performed with the Acinetobacter baumannii strain using the method of item no. 4 above. The results are illustrated in FIG. 7.

[0142] As illustrated in FIG. 6, the bacteriophage YMC14/01/P117_ABA_BP according to the present invention exhibited high stability in all conditions which are acidic, neutral, and alkaline.

[0143] In addition, as illustrated in FIG. 7, the bacteriophage YMC14/01/P117_ABA_BP exhibited very high stability up to a temperature as high as 70° C.

[0144] 8. Whole-Genome Sequencing of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0145] To characterize the bacteriophage YMC14/01/P117_ABA_BP according to the present invention, whole-genome sequencing thereof was performed through the Illumina sequencer (Roche) based on a whole-genome sequencing method which is obvious to those skilled in the art. The results are shown in FIG. 8 and Table 4.

TABLE-US-00004 TABLE 4 NCBI Initi- blastP NCBI-Bank Genome Range ation Length Putative Annotation E- identity accession no. Start End codon Strand (bp) function source value (%) number ORF1 445 1629 ATG − 1185 Putative baseplate Acinetobacter phage 0 99 AFV51558.1 J-like protein IME-AB2 ORF2 1626 1979 ATG − 354 Hypothetical protein Acinetobacter phage 3E−81 99 ADO14451.1 AB1 ORF3 2125 2796 ATG − 672 Putative baseplate Acinetobacter phage  2E−157 100 YP_009055472.1 assembly protein YMC-13-01-C62 ORF4 2753 3643 GTG − 891 Hypothetical protein Acinetobacter phage 0 94 ADO14453.1 AB1 ORF5 3752 4093 ATG − 342 Hypothetical protein Acinetobacter phage 5E−60 99 ARB06749.1 WCHABP12 ORF6 4032 4628 ATG − 597 Hypothetical protein Acinetobacter phage  2E−139 98 ADO14454.1 AB1 ORF7 4636 6684 ATG − 2049 Lysozyme like Acinetobacter phage 0 100 YP_009055475.1 domain protein YMC-13-01-C62 ORF8 6687 6929 GTG − 243 Putative tail- Acinetobacter phage 3E−52 99 YP_009055476.1 fiber/lysozyme YMC-13-01-C62 protein ORF9 6929 7354 ATG − 426 Hypothetical protein Acinetobacter phage 1E−37 46 ADO14372.1 AB1 ORF10 7400 7949 ATG − 550 Hypothetical protein Acinetobacter phage 2E−59 58 ADO14373.1 AB1 ORF11 7862 9325 ATG − 1464 Hypothetical protein Acinetobacter phage 0 98 ADO14374.1 AB1 ORF12 9315 9809 ATG − 495 Hypothetical protein Acinetobacter phage  3E−110 93 ADO14375.1 AB1 ORF13 9806 10276 ATG − 471 Hypothetical protein Acinetobacter phage  3E−108 96 ADO14377.1 AB1 ORF14 10354 10635 ATG − 282 Putative capsid Acinetobacter phage 3E−55 100 YP_009055482.1 protein YMC-13-01-C62 ORF15 10683 10868 ATG − 186 Hypothetical protein Acinetobacter phage 8E−31 90 ADO14379.1 AB1 ORF16 10865 11371 ATG − 507 Putative RNA Acinetobacter phage 5E−98 94 ARB06827.1 polymerase IME-AB2 ORF17 11878 12102 ATG + 225 Hypothetical protein Acinetobacter phage 4E−47 100 AFV51493.1 IME-AB2 ORF18 12270 12545 ATG − 276 Hypothetical protein Acinetobacter phage 2E−58 98 YP_006383783.1 AP22 ORF19 12561 13010 ATG − 450 Hypothetical protein Acinetobacter phage 1E−84 80 ADO14383.1 AB1 ORF20 13010 13348 ATG − 339 Hypothetical protein Acinetobacter phage 3E−21 43 ADO14384.1 AB1 ORF21 13428 14447 ATG − 1020 Hypothetical protein Acinetobacter phage 0 100 YP_009055489.1 YMC-13-01-C62 ORF22 14457 14936 ATG − 480 Hypothetical protein Acinetobacter phage 2E−31 44 ADO14387.1 AB1 ORF23 14944 16278 ATG − 1335 Hypothetical protein Acinetobacter phage 0 81 ADO14388.1 AB1 ORF24 16492 16698 ATG − 207 Hypothetical protein Acinetobacter phage 1E−43 100 YP_009055493.1 YMC-13-01-C62 ORF25 16688 16963 ATG − 276 Hypothetical protein Acinetobacter phage 6E−61 100 YP_009055494.1 YMC-13-01-C62 ORF26 17062 17424 ATG − 363 Hypothetical protein Acinetobacter phage 2E−84 100 YP_009055495.1 YMC-13-01-C62 ORF27 17421 17813 ATG − 393 Hypothetical protein Acinetobacter phage 1E−89 100 AJT61472.1 YMC11/12/R1215 ORF28 17806 18228 ATG − 423 ORF29 18218 18571 ATG − 354 Hypothetical protein Acinetobacter phage 4E−83 100 YP_009055498.1 YMC-13-01-C62 ORF30 18653 18763 ATG − 111 Hypothetical protein Acinetobacter phage 3E−27 100 YP_009055499.1 YMC-13-01-C62 0RF31 18800 18964 ATG − 165 Hypothetical protein Acinetobacter phage 7E−32 100 YP_009055500.1 YMC-13-01-C62 ORF32 19654 20424 ATG − 771 Putative head Acinetobacter phage 0 99 ASJ78923.1 protein AbP2 ORF33 20427 21557 ATG − 1131 Putative portal Acinetobacter phage 0 95 ARB06806.1 protein WCHABP12 ORF34 21574 21930 ATG − 357 Putative portal Acinetobacter phage 9E−80 99 ARB06806.1 protein WCHABP12 ORF35 21934 23235 ATG − 1302 Putative phage Acinetobacter phage 0 94 YP_006383766.1 terminase AP22 large subunit ORF36 23204 23569 ATG − 366 DNA binding domain uncultured 2E−12 41 BAQ88996.1 Mediterranean phage uvMED ORF37 23562 24755 GTG − 1194 ParB/sulfiredoxin Vibrio phage  4E−138 58 AUR95847.1 1.213.O._10N.222.54.F10 ORF38 24807 25070 ATG − 264 Hypothetical protein Acinetobacter phage 2E−32 96 ASJ78929.1 AbP2 ORF39 25175 25354 ATG − 180 Hypothetical protein Acinetobacter phage 7E−09 49 YP_009055426.1 YMC-13-01-C62 ORF40 25357 25683 ATG − 327 Hypothetical protein Acinetobacter phage 4E−74 100 AJT61457.1 YMC11/12/R1215 ORF41 26010 26348 ATG − 339 Hypothetical protein Acinetobacter phage 2E−79 100 YP_009055430.1 YMC-13-01-C62 ORF42 26421 26660 ATG − 240 Hypothetical protein Acinetobacter phage 5E−44 96 ADO14411.1 AB1 ORF43 26801 27088 ATG − 288 Hypothetical protein Acinetobacter phage 2E−59 96 ADO14413.1 AB1 ORF44 27069 27329 ATG − 261 Hypothetical protein Acinetobacter phage 3E−56 100 YP_009055433.1 YMC-13-01-C62 ORF45 27326 27712 ATG − 387 Hypothetical protein Acinetobacter phage 1E−21 42 ADO14414.1 AB1 ORF46 27699 28280 ATG − 582 Hypothetical protein Acinetobacter phage  5E−141 100 YP_009055435.1 YMC-13-01-C62 ORF47 28277 28441 ATG − 165 Hypothetical protein Acinetobacter phage 2E−24 89 ADO14416.1 AB1 ORF48 28438 29013 ATG − 576 Hypothetical protein Acinetobacter phage  1E−137 98 ADO14417.1 AB1 ORF49 29010 29777 ATG − 768 Hypothetical protein Acinetobacter phage  2E−134 79 ADO14418.1 AB1 ORF50 29765 29878 ATG − 114 Hypothetical protein Acinetobacter phage 2E−16 92 ADO14419.1 AB1 ORF51 29875 30087 ATG − 213 Putative Acinetobacter phage 2E−41 99 AFV51531.1 bacteriophage- IME-AB2 associated immunity protein ORF52 30159 30308 ATG − 150 Hypothetical protein Acinetobacter phage   0.32 41 YP_009055440.1 YMC-13-01-C62 ORF53 30305 30598 ATG − 294 Hypothetical protein Acinetobacter phage 3E−58 91 ADO14421.1 AB1 ORF54 30595 30864 ATG − 270 Hypothetical protein Acinetobacter phage 4E−35 63 ADO14422.1 AB1 ORF55 30875 32218 ATG − 1344 Putative replicative Acinetobacter phage 0 99 YP_009055443.1 DNA helicase YMC-13-01-C62 ORF56 32224 33090 ATG − 867 Putative primosomal Acinetobacter phage 0 99 AFV51535.1 protein IME-AB2 ORF57 33083 33562 ATG − 480 Hypothetical protein Acinetobacter phage  2E−113 100 YP_009055445.1 YMC-13-01-C62 ORF58 33575 33787 ATG − 213 Hypothetical protein Acinetobacter phage 2E−38 87 ADO14425.1 AB1 ORF59 33802 34137 ATG − 336 Hypothetical protein Acinetobacter phage 8E−76 100 YP_009055447.1 YMC-13-01-C62 ORF60 34321 34509 ATG − 189 Hypothetical protein Acinetobacter phage 1E−21 86 ADO14428.1 AB1 ORF61 34703 35290 ATG + 588 Putative HNH homing Acinetobacter phage 3E−61 50 ASJ78942.1 endonuclease AbP2 ORF62 35343 35537 ATG − 195 Hypothetical protein Acinetobacter phage 3E−14 52 ADO14431.1 AB1 ORF63 35637 36449 ATG + 813 Putative Acinetobacter phage 0 100 YP_009055451.1 transcriptional YMC-13-01-C62 regulator ORF64 36504 36773 ATG + 270 Hypothetical protein Acinetobacter phage 6E−47 88 ADO14434.1 AB1 ORF65 36866 37198 ATG + 333 Hypothetical protein Acinetobacter phage 1E−68 94 ADO14435.1 AB1 ORF66 37198 37380 ATG + 183 Hypothetical protein Acinetobacter phage 2E−36 100 YP_009055454.1 YMC-13-01-C62 ORF67 37377 38276 ATG + 900 Hypothetical protein Psychrobacter phage 1E−70 43 YP_007673324.1 pOW20-A ORF68 38273 39028 ATG + 756 Hypothetical protein Acinetobacter phage  2E−169 97 ADO14438.1 AB1 ORF69 39029 39322 ATG + 294 Hypothetical protein Acinetobacter phage 7E−61 96 ADO14439.1 AB1 ORF70 39319 39540 ATG + 222 Hypothetical protein Acinetobacter phage 2E−07 43 YP_009055458.1 YMC-13-01-C62 ORF71 39537 39698 ATG + 162 Hypothetical protein Acinetobacter phage 3E−29 96 ADO14441.1 AB1 ORF72 39686 40258 ATG + 573 Putative nucleoside Acinetobacter phage 5E−71 64 AFV51550.1 triphosphate IME-AB2 pyrophosphohydrolase ORF73 40251 40481 ATG + 231 rIIB lysis inhibitor Caulobacter phage   1.6 33 AXQ68725.1 CcrPW ORF74 40574 41182 ATG − 609 Putative endolysin Acinetobacter phage  5E−143 98 ARB06760.1 WCHABP12 ORF75 41169 41444 ATG − 276 Hypothetical protein Acinetobacter phage 1E−56 95 ADO14445.1 AB1 ORF76 41428 41748 ATG − 321 Hypothetical protein Acinetobacter phage 1E−53 95 ADO14446.1 AB1 ORF77 41824 43647 ATG − 1824 Putative tail fiber Acinetobacter phage 2E−77 88 ARQ94726.1 protein WCHABP1 ORF78 43649 44494 GTG − 846 Putative tail fiber Acinetobacter phage 0 99 YP_009203603.1 protein YMC11/12/R2315

[0146] As shown in FIG. 8 and Table 4, the bacteriophage YMC14/01/P117_ABA_BP contained linear dsDNA and was composed of 78 ORFs.

[0147] As a result of comparing the sequence of the bacteriophage YMCT4/01/P117_ABA_BP according to the present invention with sequences of the existing bacteriophages, no bacteriophage having similarity to the bacteriophage according to the present invention was detected. From the above results, it can be seen that the bacteriophage YMCT4/01/P117_ABA_BP according to the present invention corresponds to a novel bacteriophage that has not been previously discovered.

[Example 2] Bacteriophage YMC16/12/R4637 ABA_BP

[0148] 1. Isolation of Clinical Specimens and Selection of Antibiotic-Resistant Strains

[0149] As shown in Table 5 below, Acinetobacter baumannii strains were isolated from blood, clinical specimens, and the like obtained from the intensive care unit (ICU) of a university hospital, and cultured. Strain identification was performed using a kit such as ATB 32 GN system (bioMérieux, Marcy l'Etoile, France). Subsequently, for antibiotic susceptibility test, a CLSI disk diffusion test method, in which culture is performed overnight at 37° C. in outside air using Mueller-Hinton agar, was used; and for test antibiotics, amikacin, ampicillin-sulbactam, ceftazidime, ciprofloxacin, colistin, cefepime, cefotaxime, gentamicin, imipenem, levofloxacin, meropenem, minocycline, piperacillin, piperacillin-tazobactam, cortrimoxa, and tigecycline were used. The susceptibility results were read based on the Clinical and Laboratory Standards Institute (CLSI, 2016). Antibiotic resistance profiles of the collected Acinetobacter baumannii strains are shown in Table 6 below. In Table 6 below, S, I, and R are the results obtained by evaluating susceptibility to the antibacterial agents, in which ‘S’ means susceptible, ‘I’ means intermediate, and ‘R’ means resistant.

TABLE-US-00005 TABLE 5 Host strain Origin of sample Host strain Origin of sample YMC16/12/R12914 Sputum (pneumonia) YMC16/01/R198 Sputum (pneumonia) YMC16/12/B11422 Catheter blood YMC16/01/R353 Tracheal aspirate (pneumonia) YMC16/12/B11449 Blood YMC16/01/R405 Sputum (pneumonia) YMC16/12/B10832 Blood YMC16/01/R397 Sputum (pneumonia) YMC16/12/B13325 Catheter blood YMC16/01/R380 Tracheal aspirate (pneumonia) YMC17/01/P518 Swab or drainage tube, hip YMC16/12/R4637 Swab or drainage tube, abdomen YMC17/01/B8053 Catheter blood YMC17/01/R2812 Tracheal tube tip YMC17/01/B10087 Catheter blood YMC17/02/R541 Tracheal aspirate (pneumonia) YMC17/01/B12075 Catheter blood YMC17/02/R2392 Sputum (pneumonia) YMC17/02/B14 Blood YMC17/03/R348 Sputum (pneumonia) YMC17/01/B13454 Blood YMC17/03/R5305 YMC17/02/B87 Blood YMC17/03/R3095 YMC17/02/B721 Blood YMC17/03/R3428 YMC17/02/B4520 Catheter blood YMC17/03/R4607 Sputum (pneumonia) YMC17/02/B4039 Blood YMC17/03/P971 Swab or drainage tube, hip YMC17/02/B4864 Blood YMC16/03/R4461 Tracheal aspirate (pneumonia) YMC17/02/P523 Decubitus ulcer YMC16/05/R2210 Sputum (pneumonia) YMC17/02/B8414 Peritoneal-blood bottle YMC16/07/R2512 Bronchoalveolar lavage YMC17/03/R585 Sputum (pneumonia) YMC16/09/R2471 Tracheal aspirate (pneumonia) YMC17/03/B4730 Catheter blood YMC16/10/R2537 Sputum (pneumonia) YMC17/03/B5000 Catheter blood YMC16/12/P503 Swab or drainage tube, chest YMC17/03/R1888 Sputum (pneumonia) YMC15/02/T28 Another catheter tip YMC17/03/R3279 Sputum (pneumonia) YMC15/02/R436 Tracheal aspirate (pneumonia) YMC17/03/R4077 Tracheal aspirate YMC15/03/R1604 Tracheal aspirate (pneumonia) (pneumonia) YMC17/04/R488 Sputum (pneumonia) YMC15/09/R1869 Sputum (pneumonia) YMC17/04/R640 Sputum (pneumonia) YMC14/06/R2359 Sputum (pneumonia) YMC/17/05/R1095 Tracheal aspirate YMC14/08/T90 Another catheter tip (pneumonia) YMC16/01/P11 Swab or drainage tube, hip YMC14/08/R1169 Sputum (pneumonia) YMC16/01/R123 Tracheal tube tip

TABLE-US-00006 TABLE 6 Host Ampicillin- strain Amikacin sulbactam Ceftazidime Ciprofloxacin Colistin Cefepime Cefotaxime Gentamicin Imipenem YMC16/12/ R12914 YMC16/12/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B11422 YMC16/12/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B11449 YMC16/12/ B10832 YMC16/12/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B13325 YMC17/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R P518 YMC17/01/ 6 R    8 S =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B8053 YMC17/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B10087 YMC17/01/ 22 S    16 I =64 R =4 R   22 S =64 R =64 R  =1 S =16 R B12075 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B14 YMC17/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B13454 YMC17/02/ 20 S    16 I =64 R =4 R  =0.5 S =64 R =64 R    2 S =16 R B87 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B721 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B4520 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B4039 YMC17/02/ 25 S   =2 S    4 S   =0.25 S  =0.5 S    2 S    8 S  =1 S  =0.25 S B4864 YMC17/02/ 21 S    16 I =64 R =4 R  =0.5 S =64 R =64 R    4 S =16 R P523 YMC17/02/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B8414 YMC17/03/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R585 YMC17/03/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B4730 YMC17/03/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B5000 YMC17/03/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1888 YMC17/03/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R3279 YMC17/03/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R4077 YMC17/04/ 6 R   16 I =64 R =4 R    8 R =64 R =64 R =16 R =16 R R488 YMC17/04/ 6 R   16 I =64 R =4 R    8 R =64 R =64 R =16 R =16 R R640 YMC/17/05/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1095 YMC16/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R P11 YMC16/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R123 YMC16/01/ 6 R    8 S =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R198 YMC16/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R353 YMC16/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R405 YMC16/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R397 YMC16/01/ =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R380 YMC16/12/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R4637 YMC17/01/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2812 YMC17/02/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R541 YMC17/02/ 6 R =32 R =64 R =4 R    4 R =64 R =64 R =16 R =16 R R2392 YMC17/03/ 6 R   16 I   32 R =4 R    4 R =64 R =64 R =16 R =16 R R348 YMC17/03/ R5305 YMC17/03/ R3095 YMC17/03/ R3428 YMC17/03/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R4607 YMC17/03/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R P971 YMC16/03/ 6 R    4 S =64 R =4 R =16 R =64 R   32 I =16 R =16 R R4461 YMC16/05/   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2210 YMC16/07/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2512 YMC16/09/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2471 YMC16/10/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2537 YMC16/12/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R P503 YMC15/02/ 6 R   16 I =64 R =4 R =16 R   32 R =64 R =16 R =16 R T28 YMC15/02/ 6 R =32 R =64 R =4 R    8 R =64 R =64 R =16 R =16 R R436 YMC15/03/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1604 YMC15/09/ 6 R   16 I =64 R =4 R =16 R   32 R =64 R =16 R =16 R R1869 YMC14/06/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2359 YMC14/08/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R T90 YMC14/08/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1169 Host Piperacillin- strain Levofloxacin Meropenem Minocycline Piperacillin tazobactam Cortrimoxa Tigecycline YMC16/12/ R12914 YMC16/12/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S B11422 YMC16/12/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S B11449 YMC16/12/ B10832 YMC16/12/ =8 R =16 R =1 S =128 R =128 R =320 R 1 S B13325 YMC17/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S P518 YMC17/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   B8053 YMC17/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S B10087 YMC17/01/ =8 R =16 R =1 S =128 R =128 R =20 S 2 S B12075 YMC17/02/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S B14 YMC17/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S B13454 YMC17/02/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S B87 YMC17/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S B721 YMC17/02/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S B4520 YMC17/02/ =8 R =16 R =1 S =128 R =128 R    80 R  =0.5 S B4039 YMC17/02/   =0.12 S   =0.25 S =1 S    8 S  =4 S =20 S   =0.5 S B4864 YMC17/02/ =8 R =16 R =1 S =128 R =128 R =20 S  1 S P523 YMC17/02/ =8 R =16 R   2 S =128 R =128 R =320 R =8 R   B8414 YMC17/03/ =8 R =16 R =16 R =128 R =128 R =320 R 4 I R585 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   B4730 YMC17/03/ =8 R =16 R   8 I =128 R =128 R =320 R 1 S B5000 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R1888 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R 1 S R3279 YMC17/03/ =8 R =16 R   2 S =128 R =128 R =320 R =8 R   R4077 YMC17/04/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R488 YMC17/04/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R640 YMC/17/05/ =8 R =16 R   2 S =128 R =128 R =320 R 4 I R1095 YMC16/01/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S P11 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R123 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R198 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R353 YMC16/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R405 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R397 YMC16/01/ =8 R =16 R   4 S =128 R =128 R =20 S 2 S R380 YMC16/12/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R4637 YMC17/01/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R2812 YMC17/02/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R541 YMC17/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2392 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R  =0.5 S R348 YMC17/03/ R5305 YMC17/03/ R3095 YMC17/03/ R3428 YMC17/03/ =8 R =16 R =16 R  =128 R =128 R =320 R 2 S R4607 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   P971 YMC16/03/ =8 R =16 R =1 S =128 R =128 R =320 R 4 I R4461 YMC16/05/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2210 YMC16/07/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2512 YMC16/09/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R2471 YMC16/10/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R2537 YMC16/12/ =8 R =16 R =16 R  =128 R =128 R =320 R 2 S P503 YMC15/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S T28 YMC15/02/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R436 YMC15/03/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R1604 YMC15/09/ =8 R =16 R =1 S =128 R =128 R =320 R 4 I R1869 YMC14/06/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2359 YMC14/08/ =8 R =16 R   2 S =128 R =128 R =320 R 2 S T90 YMC14/08/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R1169

[0150] As shown in Table 6, the collected 57 Acinetobacter baumannii strains were found to be multi-drug-resistant strains having resistance to various antibiotics.

[0151] 2. Collection of Bacteriophage Specimens

[0152] 2-1. Collection of Specimens to Construct Phage Bank

[0153] Raw water was obtained by causing sewage to pass through a first sedimentation tank at the sewage treatment facility of the Severance Hospital (Korea), and then removing suspended substances and sediments therefrom. The sewage was limited to sewage that was present at a preliminary stage of a chemical treatment facility. To the collected sample was added 58 g of sodium chloride per L. Then, centrifugation was performed at 10,000 g for 10 minutes and filtration was performed through a 220 nm Millipore filter. To the obtained filtrate was added polyethylene glycol (PEG, molecular weight of 8000) at 10% w/v, and the resultant was stored refrigerated at 4° C. for 12 hours. The filtrate stored refrigerated for 12 hours was centrifuged at 12,000 g for 20 minutes, and the precipitate was resuspended in phage dilution buffer (SM buffer). To the resuspension was then added the same amount of chloroform, and the resultant was stored frozen. This was repeated three times to collect 300 mL of bacteriophage suspension.

[0154] 2-2. Selection of Lytic Phage and Measurement of Lysis Titer

[0155] Separation and purification of lytic phage were performed by a spot test method (Mazzocco A et al. In Bacteriophages, Clokie and Kropinski AM, eds. Humana Press. 2009). The obtained strains were inoculated on MacConkey Agar medium and then cultured overnight at 35° C. in outside air. After the culture, strains susceptible to phage were selected by observing formation of clear plaque. The susceptible strains were inoculated on MacConkey Agar medium and cultured at 35° C. for 12 hours. A suspension of each strain was prepared in a 1 ml saline tube with a turbidity of 0.5 McFarland, and mixed with H top agar (3 ml), 100 μl of sensitive bacteria, and a phage solution (each of 1 μl, 10 μl, and 50 μl). The mixture was applied to LB agar, and then cultured at 35° C. for 12 hours. Plaque was observed, and then the plaque was collected with a Pasteur pipette. The collected plaque was diluted in SM buffer solution, and repeatedly purified three times using the susceptible strain suspension again. The thus obtained pure bacteriophage, YMC16/12/R4637_ABA_BP, was diluted in SM buffer solution, and repeatedly purified three times using the susceptible strain suspension again. The thus obtained pure bacteriophage, YMC16/12/R4637_ABA_BP, was diluted in SM buffer solution and stored.

[0156] Each of the antibiotic-resistant Acinetobacter baumannii strains identified in item no. 1. above was inoculated on MacConkey Agar medium and cultured. Then, the bacteriophage YMC16/12/R4637_ABA_BP, which had been purified by the above process, was inoculated in an amount of 5 μl into each smeared resistant strain. Then, plaque formation was checked and a titer range thereof was checked. The lysis of each strain is shown in Table 7 below.

[0157] In Table 7 below, an evaluation result of plaque activity against the collected strains is indicated by + and −, in which ‘+’ means clear plaque and ‘-’ means that lysis has not occurred.

TABLE-US-00007 TABLE 7 Host strain Lysis Host strain Lysis YMC16/12/B13325 + YMC16/01/R397 + YMC17/01/P518 + YMC17/03/R348 + YMC17/01/B8053 + YMC17/03/R3095 + YMC17/01/B10087 + YMC17/03/R3428 ++ YMC17/01/B12075 + YMC17/03/P971 + YMC17/02/B4520 + YMC16/03/R4461 ++ YMC17/02/P523 + YMC16/05/R2210 ++ YMC17/02/B8414 + YMC16/07/R2512 ++ YMC17/03/R1888 + YMC16/09/R2471 ++ YMC17/03/R3279 + YMC16/10/R2537 + YMC17/03/R4077 + YMC15/02/T28 + YMC17/04/R640 + YMC15/03/R1604 ++ YMC/17/05/R1095 + YMC15/09/R1869 + YMC16/01/P11 + YMC14/06/R2359 + YMC16/01/R123 + YMC14/08/T90 ++ YMC16/01/R198 + YMC14/08/R1169 + YMC16/01/R353 +

[0158] As shown in Table 7, it was found that the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention lyses antibiotic-resistant Acinetobacter baumannii strains.

[0159] 3. Electron Microscopic Analysis of Lytic Bacteriophage Against Antibiotic-Resistant Acinetobacter baumannii Strains

[0160] The bacteriophage YMC16/12/R4637_ABA_BP purified by the method of item no. 2. above was inoculated and cultured in culture medium (20 ml of LB medium) for susceptible strains, and then filtered through a 220 nm Millipore filter. To the supernatant was added polyethylene glycol (MW 8,000) in an amount of 10% (w/v), and then the resultant was stored refrigerated overnight. Subsequently, centrifugation was performed for 20 minutes at 12,000 g, and then a shape of the bacteriophage YMC16/12/R4637_ABA_BP was analyzed using an energy-filtering transmission electron microscope. The result is illustrated in FIG. 9.

[0161] As illustrated in FIG. 9, in a case where classification is made on a shape basis, the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention was classified as belonging to the family Myoviridae that has a long tail with a hexagonal head.

[0162] 4. Analysis of Adsorption Capacity and One-Step Growth Curve of Bacteriophage

[0163] The antibiotic-resistant Acinetobacter baumannii strain was cultured to an OD value of 0.5. To the Acinetobacter baumannii strain was then added the bacteriophage YMC16/12/R4637_ABA_BP purified in item no. 2. above at an MOI of 0.001 and culture was performed at room temperature. Then, sample was collected 1 ml each at 1, 2, 3, 4, and 5 minutes, diluted in LB medium, and then adsorption capacity of the bacteriophage was evaluated through plaque analysis. The results are illustrated in FIG. 10.

[0164] In addition, the antibiotic-resistant Acinetobacter baumannii strain was cultured to an OD value of 0.3, and then centrifuged at 7,000 g for 5 minutes at 4° C., to precipitate the cells. Then, the cells were diluted in 0.5 ml of LB medium. To the dilute was added the bacteriophage YMC16/12/R4637_ABA_BP purified in item no. 2. above at an MOI of 0.001 (titer of 10′ pfu/cell), and culture was performed at 37° C. for 5 minutes. The cultured mixed sample was centrifuged at 13,000 g for 1 minute to obtain a pellet. The obtained pellet was diluted in 10 ml of LB medium and cultured at 37° C. Samples were collected every 10 minutes during the culture, and a one-step growth curve of the bacteriophage was evaluated through plaque analysis. The results are illustrated in FIG. 11.

[0165] As illustrated in FIG. 10, about 95% of the bacteriophage YMC16/12/R4637_ABA_BP was adsorbed to the Acinetobacter baumannii strain within 10 minutes after inoculation of the bacteriophage.

[0166] In addition, as illustrated in FIG. 11, the one-step growth curve showed a high burst size of approximately 106 PFU/infected cells.

[0167] From the above results, it can be seen that the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention can be adsorbed in a relatively short time to an antibiotic-resistant Acinetobacter baumannii strain and can show a high burst size of 106 PFU/infected cells, indicating that this bacteriophage exerts a lytic effect on an antibiotic-resistant strain.

[0168] 5. Verification of In Vivo Lysis Ability of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0169] 200 third- to fourth-instar Galleria mellonella larvae were prepared, and then divided into groups, each containing 10 larvae. Each larva was injected through its proleg with a carbapenem-resistant Acinetobacter baumannii strain at a minimum lethal dose (MLD), and then subjected to mixed inoculation with the bacteriophage YMC16/12/R4637_ABA_BP purified in item no. 2. above at an MOI of 10 or an MOI of 100. Then, survival of the larvae was checked every 12 or 24 hours until 72 hours, and the results are illustrated in FIG. 12.

[0170] As illustrated in FIG. 12, it was found that in a case where the larvae injected with the carbapenem-resistant Acinetobacter baumannii strain are treated with the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention, survival of the larvae increases, in which the survival of the larvae further increases as the MOI value increases. In addition, it was found that even in a case where the larvae are injected with only the bacteriophage YMC16/12/R4637_ABA_BP without injection of the carbapenem-resistant Acinetobacter baumannii strain, no toxicity is seen when survival thereof is compared with that of a healthy control group.

[0171] From the above results, it can be seen that the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention also has lytic properties in vivo against an antibiotic-resistant Acinetobacter baumannii strain, and thus can effectively prevent, ameliorate, or treat an infectious disease caused by the Acinetobacter baumannii strain.

[0172] 6. Evaluation of Stability of Bacteriophage Against Antibiotic-Resistant Acinetobacter Baumannii Strain

[0173] It was identified whether the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention maintains stability without being destroyed under alkaline and temperature conditions.

[0174] 1 μl of the bacteriophage YMC16/12/R4637_ABA_BP purified by the method of item no. 2 above was added to 40 μl of SM buffer, which had been adjusted to a pH of 4, 5, 6, 7, 8, 9, or 10, and then incubated at 37° C. for 1 hour. Then, plaque analysis was performed with the antibiotic-resistant Acinetobacter baumannii bacteria using the method of item no. 4 above. The results are illustrated in FIG. 13.

[0175] In addition, during 1-hour incubation of the bacteriophage YMC16/12/R4637_ABA_BP solution at 4° C., 37° C., 50° C., 60° C., and 70° C., respectively, each sample was collected every 10 minutes and plaque analysis was performed with the Acinetobacter baumannii strain using the method of item no. 4 above. The results are illustrated in FIG. 14.

[0176] As illustrated in FIG. 13, the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention exhibited high stability in all conditions which are acidic, neutral, and alkaline.

[0177] In addition, as illustrated in FIG. 14, the bacteriophage YMC16/12/R4637_ABA_BP exhibited very high stability up to a temperature as high as 60° C.

[0178] 7. Whole-Genome Sequencing of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0179] To characterize the bacteriophage YMC16/12/R4637_ABA_BP according to the present invention, whole-genome sequencing thereof was performed through the Illumina sequencer (Roche) based on a whole-genome sequencing method which is obvious to those skilled in the art. The results are shown in FIG. 15 and Table 8.

TABLE-US-00008 TABLE 8 NCBI Initi- blastP NCBI-Bank Genome Range ation Length Putative Annotation E- identity accession no. Start End codon Strand (bp) function source value (%) number ORF1 5 394 ATG − 390 Hypothetical protein Acinetobacter phage 3E−88 100 YP_009055422.1 YMC-13-01-C62 ORF2 448 630 ATG − 183 Hypothetical protein Acinetobacter phage 4 88 ADO14405.1 AB1 ORF3 627 800 ATG − 174 ORF4 815 1057 ATG − 243 Hypothetical protein Acinetobacter phage 1E−47 93 ADO14406.1 AB1 ORF5 1054 1251 ATG − 198 Fis family Acinetobacter phage 3E−33 91 ARB06798.1 transcriptional WCHABP12 regulator ORF6 1254 1580 ATG − 327 Hypothetical protein Acinetobacter phage 4E−74 100 AJT61457.1 YMC11/12/R1215 ORF7 1580 1795 GTG − 216 Hypothetical protein Acinetobacter phage 2E−44 99 AFV51519.1 IME-AB2 ORF8 1907 2254 ATG − 348 Hypothetical protein Acinetobacter phage 2E−78 99 YP_009055430.1 YMC-13-01-C62 ORF9 2318 2557 ATG − 240 Hypothetical protein Acinetobacter phage 2E−45 100 YP_009055431.1 YMC-13-01-C62 ORF10 2698 2985 GTG − 288 tRNA endonuclease- Vibrio phage 2E−17 48 AUR89331.1 like domain protein 1.122.A._10N.286.46.F8 ORF11 2966 3226 ATG − 261 Hypothetical protein Acinetobacter phage 3E−56 100 YP_009055433.1 YMC-13-01-C62 ORF12 3223 3483 ATG − 261 Hypothetical protein Acinetobacter phage 6E−08 40 ADO14414.1 AB1 ORF13 3480 4235 ATG − 756 Hypothetical protein Acinetobacter phage  2E−134 79 ADO14418.1 AB1 ORF14 4345 4557 ATG − 213 Putative Acinetobacter phage 2E−41 99 AFV51531.1 bacteriophage- IME-AB2 associated immunity protein ORF15 4629 4778 ATG − 150 Hypothetical protein Acinetobacter phage 0.32 41 YP_009055440.1 YMC-13-01-C62 ORF16 4775 5068 ATG − 294 Hypothetical protein Acinetobacter phage 3E−58 91 ADO14421.1 AB1 ORF17 5068 5334 ATG − 267 Hypothetical protein Acinetobacter phage 4E−35 63 ADO14422.1 AB1 ORF18 5345 6688 ATG − 1344 Putative replicative Acinetobacter phage 0 99 YP_ 009055443.1 DNA helicase YMC-13-01-C62 ORF19 6694 7560 ATG − 867 Putative primosomal Acinetobacter phage 0 98 AFV51535.1 protein IME-AB2 ORF20 7553 8032 ATG − 480 Putative HNH Pseudomonas phage 9E−07 35 YP_007237225.1 endonuclease AF ORF21 8045 8257 ATG − 213 Hypothetical protein Acinetobacter phage 2E−38 87 ADO14425.1 AB1 ORF22 8272 8607 ATG − 336 Hypothetical protein Acinetobacter phage 8E−76 100 YP_009055447.1 YMC-13-01-C62 ORF23 8791 8979 ATG − 189 Hypothetical protein Acinetobacter phage 1E−21 86 ADO14428.1 AB1 ORF24 9173 9760 ATG + 588 Putative HNH Acinetobacter phage 3E−61 50 ASJ78942.1 homing AbP2 endonuclease ORF25 9813 10007 ATG − 195 Hypothetical protein Acinetobacter phage 3E−14 52 ADO14431.1 AB1 ORF26 10107 10919 ATG + 813 Putative Acinetobacter phage 0 100 YP_009055451.1 transcriptional YMC-13-01-C62 regulator ORF27 10986 11243 ATG + 258 Hypothetical protein Acinetobacter phage 6E−47 88 ADO14434.1 AB1 ORF28 11336 11668 ATG + 333 Hypothetical protein Acinetobacter phage 1E−68 94 ADO14435.1 AB1 ORF29 11668 11850 ATG + 183 Hypothetical protein Acinetobacter phage 2E−36 100 YP_009055454.1 YMC-13-01-C62 ORF30 11847 12746 ATG + 900 Hypothetical protein Psychrobacter phage 8E−71 43 YP_007673324.1 pOW20-A ORF31 12743 13498 ATG + 756 Hypothetical protein Acinetobacter phage  5E−166 95 ADO14438.1 AB1 ORF32 13499 13792 ATG + 294 Hypothetical protein Acinetobacter phage 2E−61 96 ADO14439.1 AB1 ORF33 13789 13971 ATG + 183 ORF34 13968 14132 ATG + 165 Hypothetical protein Acinetobacter phage 1E−27 92 ADO14441.1 AB1 ORF35 14132 14653 ATG + 522 Putative nucleoside Acinetobacter phage 1E−68 64 AFV51550.1 triphosphate IME-AB2 pyrophospho- hydrolase ORF36 14646 14876 ATG + 231 Hypothetical protein Acinetobacter phage 3E−39 82 ADO14443.1 AB1 ORF37 14975 15487 ATG − 513 Putative lysozyme Acinetobacter phage  3E−119 99 AFV51552.1 family protein IME-AB2 ORF38 15477 15749 ATG − 273 Hypothetical protein Acinetobacter phage 1E−54 94 ADO14445.1 AB1 ORF39 15733 16053 GTG − 321 Hypothetical protein Acinetobacter phage 1E−68 95 ADO14446.1 AB1 ORF40 16127 18541 ATG − 2415 Putative tail fiber Acinetobacter phage 0 90 YP_009146765.1 YMC13/03/R2096 ORF41 18543 19412 GTG − 870 Putative tail fiber Acinetobacter phage  3E−155 79 ASJ78889.1 protein AbP2 ORF42 19390 20016 ATG − 627 Hypothetical protein Acinetobacter phage  1E−146 97 ADO14449.1 AB1 ORF43 20016 21200 ATG − 1185 Putative baseplate Acinetobacter phage 0 99 ARQ94729.1 J-like protein WCHABP1 ORF44 21197 21550 ATG − 354 Hypothetical protein Acinetobacter phage 1E−80 99 YP_009055470.1 YMC-13-01-C62 ORF45 21696 22340 ATG − 645 Putative baseplate Acinetobacter phage  1E−152 97 ARQ94731.1 assembly protein WCHABP1 ORF46 22321 23211 ATG − 891 Hypothetical protein Acinetobacter phage 0 94 ADO14453.1 AB1 ORF47 23321 23596 GTG − 276 Hypothetical protein Acinetobacter phage 2E−59 100 ASJ78898.1 AbP2 ORF48 23593 24210 ATG − 618 Hypothetical protein Acinetobacter phage  7E−131 92 ADO14454.1 AB1 ORF49 24218 26308 ATG − 2091 Lysozyme like Acinetobacter phage 0 74 YP 006383794.1 domain AP22 ORF50 26311 26523 ATG − 213 Putative tail-fiber Acinetobacter phage 6E−44 99 YP_009291892.1 protein LZ35 ORF51 26553 26978 ATG − 426 Hypothetical protein Acinetobacter phage 1E−37 46 ADO14372.1 AB1 ORF52 27024 27473 ATG − 450 Hypothetical protein Acinetobacter phage  3E−105 97 ADO14373.1 AB1 ORF53 27486 28949 ATG − 1464 Hypothetical protein Acinetobacter phage 0 95 ADO14374.1 AB1 ORF54 28939 29433 ATG − 495 Hypothetical protein Acinetobacter phage  3E−110 93 ADO14375.1 AB1 ORF55 29430 29948 ATG − 519 Hypothetical protein Acinetobacter phage  3E−108 96 ADO14377.1 AB1 ORF56 29978 30259 ATG − 282 Putative capsid Acinetobacter phage 3E−55 100 YP_009055482.1 protein YMC-13-01-C62 ORF57 30307 30492 ATG − 186 Hypothetical protein Acinetobacter phage 8E−31 90 ADO14379.1 AB1 ORF58 30489 30941 ATG − 453 Putative RNA Acinetobacter phage  5E−104 100 YP_009055484.1 polymerase YMC-13-01-C62 ORF59 30970 31155 ATG − 186 Hypothetical protein Acinetobacter phage 2E−35 100 YP_009055485.1 YMC-13-01-C62 ORF60 31229 31375 ATG − 147 Lambda family tail Acinetobacter phage 1E−24 100 YP_009055486.1 tape measure YMC-13-01-C62 protein ORF61 31421 31843 ATG − 423 Hypothetical protein Acinetobacter phage 1E−95 97 ADO14383.1 AB1 ORF62 31843 32181 ATG − 339 Hypothetical protein Acinetobacter phage 3E−21 43 ADO14384.1 AB1 ORF63 32261 33280 ATG − 1020 Hypothetical protein Acinetobacter phage 0 100 YP_009055489.1 YMC-13-01-C62 ORF64 33290 33769 ATG − 480 Hypothetical protein Acinetobacter phage 1E−30 43 ADO14387.1 AB1 ORF65 33777 35111 ATG − 1335 Hypothetical protein Acinetobacter phage 0 81 ADO14388.1 AP22 ORF66 35111 35275 ATG − 165 Hypothetical protein Acinetobacter phage 1E−30 100 YP_009055492.1 YMC-13-01-C62 ORF67 35325 35531 ATG − 207 Hypothetical protein Acinetobacter phage 1E−43 100 YP_009055493.1 YMC-13-01-C62 ORF68 35521 35796 ATG − 276 Hypothetical protein Acinetobacter phage 6E−61 100 YP_009055494.1 YMC-13-01-C62 ORF69 35895 36257 ATG − 363 Hypothetical protein Acinetobacter phage 2E−84 100 YP_009055495.1 YMC-13-01-C62 ORF70 36254 36646 ATG − 393 Hypothetical protein Acinetobacter phage 1E−89 100 AJT61472.1 YMC11/12/R1215 ORF71 36639 37061 ATG − 423 ORF72 37051 37404 ATG − 354 Hypothetical protein Acinetobacter phage 4E−83 100 YP_009055498.1 YMC-13-01-C62 ORF73 37486 37632 ATG − 147 Hypothetical protein Acinetobacter phage 3E−27 100 YP_009055499.1 YMC-13-01-C62 ORF74 37633 37797 ATG − 165 Hypothetical protein Acinetobacter phage 7E−32 100 YP_009055500.1 YMC-13-01-C62 ORF75 38487 39257 ATG − 771 Putative head Acinetobacter phage 0 99 YP_009203553.1 protein AbP2 ORF76 39260 40690 ATG − 1431 Putative portal Acinetobacter phage 0 96 ARB06806.1 protein WCHABP12 ORF77 40694 41971 ATG − 1278 Putative terminase Acinetobacter phage 0 99 YP_009055504.1 large subunit YMC-13-01-C62 ORF78 41968 42522 TGT − 555 Coil containing Vibrio phage 2E−32 35 AUR98010.1 protein 1.246.O._10N.261.54.E10

[0180] As shown in FIG. 15 and Table 8, the bacteriophage YMC16/12/R4637_ABA_BP contained linear dsDNA and was composed of 78 ORFs.

[0181] As a result of comparing the sequence of the bacteriophage YMCT16/12/R4637_ABA_BP according to the present invention with sequences of the existing bacteriophages, no bacteriophage having similarity to the bacteriophage according to the present invention was detected. From the above results, it can be seen that the bacteriophage YMCT6/12/R4637_ABA_BP according to the present invention corresponds to a novel bacteriophage that has not been previously discovered.

[Example 3] Bacteriophage YMC16/01/R2016 ABA_BP

[0182] 1. Isolation of Clinical Specimens and Selection of Antibiotic-Resistant Strains

[0183] As shown in Table 9 below, Acinetobacter baumannii strains were isolated from blood, clinical specimens, and the like obtained from the intensive care unit (ICU) of a university hospital, and cultured. Strain identification was performed using a kit such as ATB 32 GN system (bioMérieux, Marcy l'Etoile, France). Subsequently, for antibiotic susceptibility test, a CLSI disk diffusion test method, in which culture is performed overnight at 37° C. in outside air using Mueller-Hinton agar, was used; and for test antibiotics, amikacin, ampicillin-sulbactam, ceftazidime, ciprofloxacin, colistin, cefepime, cefotaxime, gentamicin, imipenem, levofloxacin, meropenem, minocycline, piperacillin, piperacillin-tazobactam, cortrimoxa, and tigecycline were used. The susceptibility results were read based on the Clinical and Laboratory Standards Institute (CLSI, 2016). Antibiotic resistance profiles of the collected Acinetobacter baumannii strains are shown in Table 10 below. In Table 10 below, S, 1, and R are the results obtained by evaluating susceptibility to the antibacterial agents, in which ‘S’ means susceptible, TI means intermediate, and ‘R’ means resistant.

TABLE-US-00009 TABLE 9 Host strain Origin of sample Host strain Origin of sample YMC16/12/R12914 Sputum (pneumonia) YMC16/01/R198 Tracheal aspirate (pneumonia) YMC16/12/B11422 Catheter blood YMC16/01/R353 Sputum (pneumonia) YMC16/12/B11449 Blood YMC16/01/R405 Sputum (pneumonia) YMC16/12/B10832 Blood YMC16/01/R397 Sputum (pneumonia) YMC16/12/B13325 Catheter blood YMC16/01/R380 Sputum (pneumonia) YMC17/01/P518 Swab or drainage tube, hip YMC16/12/R4637 Sputum (pneumonia) YMC17/01/B8053 Catheter blood YMC17/01/R2812 Sputum (pneumonia) YMC17/01/B10087 Catheter blood YMC17/02/R541 Sputum (pneumonia) YMC17/01/B12075 Catheter blood YMC17/02/R2392 Sputum (pneumonia) YMC17/02/B14 Blood YMC17/03/R348 Sputum (pneumonia) YMC17/01/B13454 Blood YMC17/03/R5305 YMC17/02/B87 Blood YMC17/03/R3095 YMC17/02/B721 Blood YMC17/03/R3428 YMC17/02/B4520 Catheter blood YMC17/03/R4607 Sputum (pneumonia) YMC17/02/B4039 Blood YMC17/03/P971 Swab or drainage tube, hip YMC17/02/B4864 Blood YMC16/03/R4461 Tracheal aspirate (pneumonia) YMC17/02/P523 Decubitus ulcer YMC16/05/R2210 Sputum (pneumonia) YMC17/02/B8414 Peritoneal-blood bottle YMC16/07/R2512 Bronchoalveolar lavage YMC17/03/R585 Sputum (pneumonia) YMC16/09/R2471 Tracheal aspirate (pneumonia) YMC17/03/B4730 Catheter blood YMC16/10/R2537 Sputum (pneumonia) YMC17/03/B5000 Catheter blood YMC16/12/P503 Swab or drainage tube, chest YMC17/03/R1888 Sputum (pneumonia) YMC15/02/T28 Another catheter tip YMC17/03/R3279 Sputum (pneumonia) YMC15/02/R436 Tracheal aspirate (pneumonia) YMC17/03/R4077 Tracheal aspirate YMC15/03/R1604 Tracheal aspirate (pneumonia) (pneumonia) YMC17/04/R488 Sputum (pneumonia) YMC15/09/R1869 Sputum (pneumonia) YMC17/04/R640 Sputum (pneumonia) YMC14/06/R2359 Sputum (pneumonia) YMC/17/05/R1095 Tracheal aspirate YMC14/08/T90 Another catheter tip (pneumonia) YMC16/01/P11 Swap or drainage tube, YMC14/08/R1169 Sputum (pneumonia) abdomen YMC16/01/R123 Tracheal tube tip

TABLE-US-00010 TABLE 10 Host Ampicillin- strain Amikacin sulbactam Ceftazidime Ciprofloxacin Colistin Cefepime Cefotaxime Gentamicin Imipenem YMC16/12/ R12914 YMC16/12/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B11422 YMC16/12/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B11449 YMC16/12/ B10832 YMC16/12/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B13325 YMC17/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R P518 YMC17/01/ 6 R    8 S =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B8053 YMC17/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B10087 YMC17/01/ 22 S    16 I =64 R =4 R   22 S =64 R =64 R =1 S  =16 R B12075 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B14 YMC17/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B13454 YMC17/02/ 20 S    16 I =64 R =4 R  =0.5 S =64 R =64 R    2 S =16 R B87 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B721 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B4520 YMC17/02/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B4039 YMC17/02/ 25 S  =2 S    4 S   =0.25 S  =0.5 S    2 S    8 S =1 S    =0.25 S B4864 YMC17/02/ 21 S    16 I =64 R =4 R  =0.5 S =64 R =64 R    4 S =16 R P523 YMC17/02/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B8414 YMC17/03/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R585 YMC17/03/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B4730 YMC17/03/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R B5000 YMC17/03/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1888 YMC17/03/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R3279 YMC17/03/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R4077 YMC17/04/ 6 R   16 I =64 R =4 R    8 R =64 R =64 R =16 R =16 R R488 YMC17/04/ 6 R   16 I =64 R =4 R    8 R =64 R =64 R =16 R =16 R R640 YMC/17/05/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1095 YMC16/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R P11 YMC16/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R123 YMC16/01/ 6 R    8 S =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R198 YMC16/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R353 YMC16/01/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R405 YMC16/01/ 6 R =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R397 YMC16/01/ =32 R =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R380 YMC16/12/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R4637 YMC17/01/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2812 YMC17/02/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R541 YMC17/02/ 6 R =32 R =64 R =4 R    4 R =64 R =64 R =16 R =16 R R2392 YMC17/03/ 6 R   16 I   32 R =4 R    4 R =64 R =64 R =16 R =16 R R348 YMC17/03/ R5305 YMC17/03/ R3095 YMC17/03/ R3428 YMC17/03/ 6 R   16 I =64 R =4 R  =0.5 S =64 R =64 R =16 R =16 R R4607 YMC17/03/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R P971 YMC16/03/ 6 R    4 S =64 R =4 R =16 R =64 R   32 I =16 R =16 R R4461 YMC16/05/   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2210 YMC16/07/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2512 YMC16/09/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2471 YMC16/10/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2537 YMC16/12/ 6 R =32 R =64 R =4 R =16 R =64 R =64 R =16 R =16 R P503 YMC15/02/ 6 R   16 I =64 R =4 R =16 R   32 R =64 R =16 R =16 R T28 YMC15/02/ 6 R =32 R =64 R =4 R    8 R =64 R =64 R =16 R =16 R R436 YMC15/03/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1604 YMC15/09/ 6 R   16 I =64 R =4 R =16 R   32 R =64 R =16 R =16 R R1869 YMC14/06/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R R2359 YMC14/08/ 6 R    8 S =64 R =4 R =16 R =64 R =64 R =16 R =16 R T90 YMC14/08/ 6 R   16 I =64 R =4 R =16 R =64 R =64 R =16 R =16 R R1169 Host Piperacillin- strain Levofloxacin Meropenem Minocycline Piperacillin tazobactam Cortrimoxa Tigecycline YMC16/12/ R12914 YMC16/12/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S B11422 YMC16/12/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S B11449 YMC16/12/ B10832 YMC16/12/ =8 R =16 R =1 S =128 R =128 R =320 R 1 S B13325 YMC17/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S P518 YMC17/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   B8053 YMC17/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S B10087 YMC17/01/ =8 R =16 R =1 S =128 R =128 R  =20 S 2 S B12075 YMC17/02/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S B14 YMC17/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S B13454 YMC17/02/ =8 R =16 R   8 I =128 R =128 R =320 R 2 S B87 YMC17/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S B721 YMC17/02/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S B4520 YMC17/02/ =8 R =16 R =1 S =128 R =128 R    80 R =0.5 S   B4039 YMC17/02/  =0.12 S  =0.25 S =1 S    8 S =4 S   =20 S =0.5 S   B4864 YMC17/02/ =8 R =16 R =1 S =128 R =128 R  =20 S 1 S P523 YMC17/02/ =8 R =16 R   2 S =128 R =128 R =320 R =8 R   B8414 YMC17/03/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R585 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   B4730 YMC17/03/ =8 R =16 R   8 I =128 R =128 R =320 R 1 S B5000 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R1888 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R 1 S R3279 YMC17/03/ =8 R =16 R   2 S =128 R =128 R =320 R =8 R   R4077 YMC17/04/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R488 YMC17/04/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R640 YMC/17/05/ =8 R =16 R   2 S =128 R =128 R =320 R 4 I R1095 YMC16/01/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S P11 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R123 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R198 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 2 S R353 YMC16/01/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R405 YMC16/01/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R397 YMC16/01/ =8 R =16 R   4 S =128 R =128 R  =20 S 2 S R380 YMC16/12/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R4637 YMC17/01/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R2812 YMC17/02/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R541 YMC17/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2392 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =0.5 S   R348 YMC17/03/ R5305 YMC17/03/ R3095 YMC17/03/ R3428 YMC17/03/ =8 R =16 R =16 R  =128 R =128 R =320 R 2 S R4607 YMC17/03/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   P971 YMC16/03/ =8 R =16 R =1 S =128 R =128 R =320 R 4 I R4461 YMC16/05/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2210 YMC16/07/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2512 YMC16/09/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R2471 YMC16/10/ =8 R =16 R =1 S =128 R =128 R   160 R 1 S R2537 YMC16/12/ =8 R =16 R =16 R  =128 R =128 R =320 R 2 S P503 YMC15/02/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S T28 YMC15/02/ =8 R =16 R =16 R  =128 R =128 R =320 R 4 I R436 YMC15/03/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R1604 YMC15/09/ =8 R =16 R =1 S =128 R =128 R =320 R 4 I R1869 YMC14/06/ =8 R =16 R =1 S =128 R =128 R =320 R 2 S R2359 YMC14/08/ =8 R =16 R   2 S =128 R =128 R =320 R 2 S T90 YMC14/08/ =8 R =16 R =1 S =128 R =128 R =320 R =8 R   R1169

[0184] As shown in Table 10, the collected 57 Acinetobacter baumannii strains were found to be multi-drug-resistant strains having resistance to various antibiotics.

[0185] 2. Collection of Bacteriophage Specimens

[0186] 2-1. Collection of Specimens to Construct Phage Bank

[0187] Raw water was obtained by causing sewage to pass through a first sedimentation tank at the sewage treatment facility of the Severance Hospital (Korea), and then removing suspended substances and sediments therefrom. The sewage was limited to sewage that was present at a preliminary stage of a chemical treatment facility. To the collected sample was added 58 g of sodium chloride per L. Then, centrifugation was performed at 10,000 g for 10 minutes and filtration was performed through a 220 nm Millipore filter. To the obtained filtrate was added polyethylene glycol (PEG, molecular weight of 8000) at 1000 w/v, and the resultant was stored refrigerated at 4° C. for 12 hours. The filtrate stored refrigerated for 12 hours was centrifuged at 12,000 g for 20 minutes, and the precipitate was resuspended in phage dilution buffer (SM buffer). To the resuspension was then added the same amount of chloroform, and the resultant was stored frozen. This was repeated three times to collect 300 mL of bacteriophage suspension.

[0188] 2-2. Selection of Lytic Phage and Measurement of Lysis Titer

[0189] Separation and purification of lytic phage were performed by a spot test method (Mazzocco A et al. In Bacteriophages, Clokie and Kropinski AM, eds. Humana Press. 2009). The obtained strains were inoculated on MacConkey Agar medium and then cultured overnight at 35° C. in outside air. After the culture, strains susceptible to phage were selected by observing formation of clear plaque. The susceptible strains were inoculated on MacConkey Agar medium and cultured at 35° C. for 12 hours. A suspension of each strain was prepared in a 1 ml saline tube with a turbidity of 0.5 McFarland, and mixed with H top agar (3 ml), 100 μl of sensitive bacteria, and a phage solution (each of 1 μl, 10 μl, and 50 μl). The mixture was applied to LB agar, and then cultured at 35° C. for 12 hours. Plaque was observed, and then the plaque was collected with a Pasteur pipette. The collected plaque was diluted in SM buffer solution, and repeatedly purified three times using the susceptible strain suspension again. The thus obtained pure bacteriophage, YMC16/01/R2016_ABA_BP, was diluted in SM buffer solution, and repeatedly purified three times using the susceptible strain suspension again. The thus obtained pure bacteriophage, YMC16/01/R2016_ABA_BP, was diluted in SM buffer solution and stored.

[0190] Each of the 57 antibiotic-resistant Acinetobacter baumannii strains identified in item no. 1. above was inoculated on MacConkey Agar medium and cultured. Then, the bacteriophage YMC16/01/R2016_ABA_BP, which had been purified by the above process, was inoculated in an amount of 5 μl into each smeared resistant strain. Then, plaque formation was checked and a titer range thereof was checked. The lysis of each strain is shown in Table 11 below. In Table 11 below, an evaluation result of plaque activity against the collected strains is indicated by + and −, in which ‘+’ means clear plaque and ‘-’ means that lysis has not occurred.

TABLE-US-00011 TABLE 11 Host strain Lysis Host strain Lysis YMC16/12/B11422 ++ YMC16/01/R198 + YMC16/12/B13325 ++ YMC16/01/R353 + YMC17/01/P518 ++ YMC16/01/R397 + YMC17/01/B8053 ++ YMC17/03/R3095 ++ YMC17/01/B12075 ++ YMC17/03/R3428 ++ YMC17/02/B4520 ++ YMC17/03/P971 ++ YMC17/02/B4039 ++ YMC16/03/R4461 + YMC17/02/P523 ++ YMC16/07/R2512 ++ YMC17/03/R585 + YMC16/10/R2537 ++ YMC17/03/B4730 + YMC15/02/T28 ++ YMC17/03/R1888 + YMC15/02/R436 + YMC17/03/R3279 + YMC15/03/R1604 + YMC17/03/R4077 + YMC15/09/R1869 + YMC17/04/R488 + YMC14/06/R2359 + YMC17/04/R640 + YMC14/08/T90 ++ YMC16/01/R123 ++ YMC14/08/R1169 +

[0191] As shown in Table 11, it was found that the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention lyses antibiotic-resistant Acinetobacter baumannii strains.

[0192] 3. Electron Microscopic Analysis of Lytic Bacteriophage Against Antibiotic-Resistant Acinetobacter baumannii Strains

[0193] The bacteriophage YMC16/01/R2016_ABA_BP purified by the method of item no. 2. above was inoculated and cultured in culture medium (20 ml of LB medium) for susceptible strains, and then filtered through a 220 nm Millipore filter. To the supernatant was added polyethylene glycol (MW 8,000) in an amount of 10% (w/v), and then the resultant was stored refrigerated overnight. Subsequently, centrifugation was performed for 20 minutes at 12,000 g, and then a shape of the bacteriophage YMC16/01/R2016_ABA_BP was analyzed using an energy-filtering transmission electron microscope. The result is illustrated in FIG. 16.

[0194] As illustrated in FIG. 16, in a case where classification is made on a shape basis, the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention was classified as belonging to the family Myoviridae that has a long tail with a hexagonal head.

[0195] 4. Analysis of Adsorption Capacity and One-Step Growth Curve of Bacteriophage

[0196] The antibiotic-resistant Acinetobacter baumannii strain was cultured to an OD value of 0.5. To the Acinetobacter baumannii strain was then added the bacteriophage YMC16/01/R2016_ABA_BP purified in item no. 2. above at an MOI of 0.001 and culture was performed at room temperature. Then, sample was collected 1 ml each at 1, 2, 3, 4, and 5 minutes, diluted in LB medium, and then adsorption capacity of the bacteriophage was evaluated through plaque analysis. The results are illustrated in FIG. 17.

[0197] In addition, the antibiotic-resistant Acinetobacter baumannii strain was cultured to an OD value of 0.3, and then centrifuged at 7,000 g for 5 minutes at 4° C., to precipitate the cells. Then, the cells were diluted in 0.5 ml of LB medium. To the dilute was added the bacteriophage YMC16/01/R2016_ABA_BP purified in item no. 2. above at an MOI of 0.001 (titer of 10.sup.8 pfu/cell), and culture was performed at 37° C. for 5 minutes. The cultured mixed sample was centrifuged at 13,000 g for 1 minute to obtain a pellet. The obtained pellet was diluted in 10 ml of LB medium and cultured at 37° C. Samples were collected every 10 minutes during the culture, and a one-step growth curve of the bacteriophage was evaluated through plaque analysis. The results are illustrated in FIG. 18.

[0198] As illustrated in FIG. 17, about 100% of the bacteriophage YMC16/01/R2016_ABA_BP was adsorbed to the Acinetobacter baumannii strain within 10 minutes after inoculation of the bacteriophage.

[0199] In addition, as illustrated in FIG. 18, the one-step growth curve showed a high burst size of 448 PFU/infected cells.

[0200] From the above results, it can be seen that the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention can be adsorbed in a relatively short time to an antibiotic-resistant Acinetobacter baumannii strain and can show a high burst size of 448 PFU/infected cells, indicating that this bacteriophage exerts a lytic effect on an antibiotic-resistant strain.

[0201] 5. Verification of In Vivo Lysis Ability of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0202] 200 third- to fourth-instar Galleria mellonella larvae were prepared, and then divided into groups, each containing 10 larvae. Each larva was injected through its proleg with a carbapenem-resistant Acinetobacter baumannii strain at a minimum lethal dose (MLD), and then subjected to mixed inoculation with the bacteriophage YMC16/01/R2016_ABA_BP purified in item no. 2. above at an MOI of 10 or an MOI of 100. Then, survival of the larvae was checked every 12 or 24 hours until 72 hours, and the results are illustrated in FIG. 19.

[0203] As illustrated in FIG. 19, it was found that in a case where the larvae injected with the carbapenem-resistant Acinetobacter baumannii strain are treated with the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention, survival of the larvae increases, in which the survival of the larvae further increases as the MOI value increases. In addition, it was found that even in a case where the larvae are injected with only the bacteriophage YMC16/01/R2016_ABA_BP without injection of the carbapenem-resistant Acinetobacter baumannii strain, no toxicity is seen when survival thereof is compared with that of a healthy control group.

[0204] From the above results, it can be seen that the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention also has lytic properties in vivo against an antibiotic-resistant Acinetobacter baumannii strain, and thus can effectively prevent, ameliorate, or treat an infectious disease caused by the Acinetobacter baumannii strain.

[0205] 6. Evaluation of Stability of Bacteriophage Against Antibiotic-Resistant Acinetobacter baumannii Strain

[0206] It was identified whether the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention maintains stability without being destroyed under alkaline and temperature conditions.

[0207] 1 μl of the bacteriophage YMC16/01/R2016_ABA_BP purified by the method of item no. 2 above was added to 40 μl of SM buffer, which had been adjusted to a pH of 4, 5, 6, 7, 8, 9, or 10, and then incubated at 37° C. for 1 hour. Then, plaque analysis was performed with the antibiotic-resistant Acinetobacter baumannii bacteria using the method of item no. 4 above. The results are illustrated in FIG. 20.

[0208] In addition, during 1-hour incubation of the bacteriophage YMC16/01/R2016_ABA_BP solution at 4° C., 37° C., 50° C., 60° C., and 70° C., respectively, each sample was collected every 10 minutes and plaque analysis was performed with the Acinetobacter baumannii strain using the method of item no. 4 above. The results are illustrated in FIG. 21.

[0209] As illustrated in FIG. 20, the bacteriophage YMCT6/01/R2016_ABA_BP according to the present invention exhibited high stability in all conditions which are acidic, neutral, and alkaline.

[0210] In addition, as illustrated in FIG. 21, the bacteriophage YMCT6/01/R2016_ABA_BP exhibited very high stability up to a temperature as high as 60° C.

[0211] 7. Whole-Genome Sequencing of Bacteriophage Against Antibiotic-Resistant Acinetobacter Genus Bacteria

[0212] To characterize the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention, whole-genome sequencing thereof was performed through the Illumina sequencer (Roche) based on a whole-genome sequencing method which is obvious to those skilled in the art. The results are shown in FIG. 22 and Table 12.

TABLE-US-00012 TABLE 12 NCBI Initi- blastP NCBI-Bank Genome Range ation Length Putative Annotation E- identity accession no. Start End codon Strand (bp) function source value (%) number ORF1 376 882 ATG + 507 Putative RNA Acinetobacter phage 5E−98 94 ARB06827.1 polymerase WCHABP12 ORF2 879 1064 ATG + 186 Hypothetical protein Acinetobacter phage 8E−31 90 ADO14379.1 AB1 ORF3 1112 1393 ATG + 282 Putative capsid Acinetobacter phage 3E−55 100 YP_009055482.1 protein YMC-13-01-C62 ORF4 1471 1941 ATG + 471 Hypothetical protein Acinetobacter phage  3E−108 96 ADO14377.1 AB1 ORF5 1938 3881 ATG + 1944 Hypothetical protein Acinetobacter phage 0 98 ADO14374.1 AB1 ORF6 3894 4343 ATG + 450 Hypothetical protein Acinetobacter phage 2E−59 58 ADO14373.1 AB1 ORF7 4389 4814 ATG + 426 Hypothetical protein Acinetobacter phage 1E−37 46 ADO14372.1 AB1 ORF8 4814 5056 GTG + 243 Putative tail-fiber/ Acinetobacter phage 3E−52 99 YP_009055476.1 lysozyme protein YMC-13-01-C62 ORF9 5056 7107 ATG + 2052 Lysozyme like Acinetobacter phage 0 100 YP_009055475.1 domain protein YMC-13-01-C62 ORF10 7115 7711 ATG + 597 Hypothetical protein Acinetobacter phage  2E−139 98 ADO14454.1 AB1 ORF11 7650 7991 ATG + 342 Hypothetical protein Acinetobacter phage 5E−60 99 ARB06749.1 WCHABP12 ORF12 8100 8990 GTG + 891 Hypothetical protein Acinetobacter phage 0 94 ADO14453.1 AB1 ORF13 8947 9618 ATG + 672 Putative baseplate Acinetobacter phage  2E−157 100 YP 009055472.1 assembly protein YMC-13-01-C62 ORF14 9764 10117 ATG + 354 Hypothetical protein Acinetobacter phage 3E−81 99 ADO14451.1 AB1 ORF15 10114 11298 ATG + 1185 Putative baseplate Acinetobacter phage 0 99 AFV51558.1 J-like protein IME-AB2 ORF16 11298 11924 ATG + 627 Hypothetical protein Acinetobacter phage  8E−149 99 ADO14449.1 AB1 ORF17 11902 12747 GTG + 846 Putative tail fiber Acinetobacter phage 0 99 YP_009203603.1 protein YMC11/12/R2315 ORF18 12749 14572 ATG + 1824 Putative tail fiber Acinetobacter phage 2E−77 88 ARQ94726.1 protein WCHABP1 ORF19 14648 14968 ATG + 321 Hypothetical protein Acinetobacter phage 7E−54 96 ADO14446.1 AB1 ORF20 14952 15227 ATG + 276 Hypothetical protein Acinetobacter phage 1E−56 95 ADO14445.1 AB1 ORF21 15214 15822 ATG + 609 Putative endolysin Acinetobacter phage  5E−143 98 ARB06760.1 WCHABP12 ORF22 15915 16145 ATG − 231 rIIB lysis inhibitor Caulobacter phage 2 33 AXQ68725.1 CcrPW ORF23 16138 16710 ATG − 573 Putative nucleoside Acinetobacter phage 5E−71 64 AFV51550.1 triphosphate IME-AB2 pyrophospho- hydrolase ORF24 16698 16859 ATG − 162 Hypothetical protein Acinetobacter phage 3E−29 96 ADO14441.1 AB1 ORF25 16856 17077 ATG − 222 Hypothetical protein Acinetobacter phage 2E−07 43 YP_009055458.1 YMC-13-01-C62 ORF26 17074 17367 ATG − 294 Hypothetical protein Acinetobacter phage 7E−61 96 ADO14439.1 AB1 ORF27 17368 18123 ATG − 756 Hypothetical protein Acinetobacter phage  2E−169 97 ADO14438.1 AB1 ORF28 18120 19019 ATG − 900 Hypothetical protein Psychrobacter phage 1E−70 43 YP_007673324.1 pOW20-A ORF29 19016 19198 ATG − 183 Hypothetical protein Acinetobacter phage 2E−36 100 YP 009055454.1 YMC-13-01-C62 ORF30 19198 19530 ATG − 333 Hypothetical protein Acinetobacter phage 1E−68 94 ADO14435.1 AB1 ORF31 19623 19892 ATG − 270 Hypothetical protein Acinetobacter phage 6E−47 88 ADO14434.1 AB1 ORF32 19947 20759 ATG − 813 Putative Acinetobacter phage 0 100 YP_009055451.1 transcriptional YMC-13-01-C62 regulator ORF33 20859 21053 ATG + 195 Hypothetical protein Acinetobacter phage 3E−14 52 ADO14431.1 AB1 ORF34 21106 21693 ATG − 588 Putative HNH Acinetobacter phage 3E−61 50 ASJ78942.1 homing AbP2 endonuclease ORF35 21887 22075 ATG + 189 Hypothetical protein Acinetobacter phage 1E−21 86 ADO14428.1 AB1 ORF36 22259 22594 ATG + 336 Hypothetical protein Acinetobacter phage 8E−76 100 YP_009055447.1 YMC-13-01-C62 ORF37 22609 22821 ATG + 213 Hypothetical protein Acinetobacter phage 2E−38 87 ADO14425.1 AB1 ORF38 22834 23313 ATG + 480 Hypothetical protein Acinetobacter phage  2E−113 100 YP_009055445.1 YMC-13-01-C62 ORF39 23306 24172 ATG + 867 Putative primosomal Acinetobacter phage 0 99 AFV51535.1 protein IME-AB2 ORF40 24178 25521 ATG + 1344 Putative replicative Acinetobacter phage 0 99 YP_009055443.1 DNA helicase YMC-13-01-C62 ORF41 25532 25801 ATG + 270 Hypothetical protein Acinetobacter phage 4E−35 63 ADO14422.1 AB1 ORF42 25864 26091 ATG + 228 Hypothetical protein Acinetobacter phage 3E−58 91 ADO14421.1 AB1 ORF43 26088 26237 ATG + 150 Hypothetical protein Acinetobacter phage  0.32 41 YP_009055440.1 YMC-13-01-C62 ORF44 26309 26521 ATG + 213 Putativebacteriophage- Acinetobacter phage 2E−41 99 AFV51531.1 associated IME-AB2 immunity protein ORF45 26518 26631 ATG + 114 Hypothetical protein Acinetobacter phage 3E−14 95 ADO14419.1 AB1 ORF46 26619 27386 ATG + 768 Hypothetical protein Acinetobacter phage  2E−134 79 ADO14418.1 AB1 ORF47 27383 27958 ATG + 576 Hypothetical protein Acinetobacter phage  1E−137 98 ADO14417.1 AB1 ORF48 27955 28119 GTG + 165 Hypothetical protein Acinetobacter phage 2E−24 89 ADO14416.1 AB1 ORF49 28116 28697 ATG + 582 Hypothetical protein Escherichia phage 1E−10 56 YP_009018683.1 EB49 ORF50 28684 29070 ATG + 387 Hypothetical protein Acinetobacter phage 1E−21 42 ADO14414.1 AB1 ORF51 29067 29327 ATG + 261 Hypothetical protein Acinetobacter phage 3E−56 100 YP_009055433.1 YMC-13-01-C62 ORF52 29308 29595 GTG + 288 tRNA endonuclease- Vibrio phage 2E−17 48 AUR89331.1 like domain protein 1.122.A._10N.286.46.F8 ORF53 29736 29975 ATG + 240 Hypothetical protein Acinetobacter phage 5E−44 96 ADO14411.1 AB1 ORF54 30048 30386 ATG + 339 Hypothetical protein Acinetobacter phage 2E−79 100 YP 009055430.1 YMC-13-01-C62 ORF55 30713 31039 ATG + 327 Hypothetical protein Acinetobacter phage 4E−74 100 AJT61457.1 YMC11/12/R1215 ORF56 31042 31221 ATG + 180 Fis family Acinetobacter phage 2E−06 45 ARB06798.1 transcriptional WCHABP12 regulator ORF57 31326 31589 ATG + 264 Hypothetical protein Acinetobacter phage 2E−32 96 ASJ78929.1 AbP2 ORF58 31641 32834 GTG + 1194 ParB/sulfiredoxin Vibrio phage  4E−138 58 AUR95847.1 1.213.O._10N.222.54.F10 ORF59 32827 33192 ATG + 366 DNA binding domain uncultured 2E−12 41 BAQ88996.1 Mediterranean phage uvMED ORF60 33161 34462 ATG + 1302 Putative phage Acinetobacter phage 0 94 YP_006383766.1 terminase AP22 large subunit ORF61 34466 35896 ATG + 1431 Putative portal Acinetobacter phage 0 96 ARB06806.1 protein WCHABP12 ORF62 35899 36669 ATG + 771 Putative head protein Acinetobacter phage 0 99 ASJ78923.1 AbP2 ORF63 37359 37523 ATG + 165 Hypothetical protein Acinetobacter phage 7E−32 100 YP_009055500.1 YMC-13-01-C62 ORF64 37560 37670 ATG + 111 Hypothetical protein Acinetobacter phage 3E−27 100 YP_009055499.1 YMC-13-01-C62 ORF65 37752 38105 ATG + 354 Hypothetical protein Acinetobacter phage 4E−83 100 YP_009055498.1 YMC-13-01-C62 ORF66 38095 38517 ATG + 423 ORF67 38510 38902 ATG + 393 Hypothetical protein Acinetobacter phage 1E−89 100 AJT61472.1 YMC11/12/R1215 ORF68 38899 39261 ATG + 363 Hypothetical protein Acinetobacter phage 2E−84 100 YP_009055495.1 YMC-13-01-C62 ORF69 39360 39635 ATG + 276 Hypothetical protein Acinetobacter phage 6E−61 100 YP 009055494.1 YMC-13-01-C62 ORF70 40045 41379 ATG + 1335 Hypothetical protein Acinetobacter phage 0 81 ADO14388.1 AB1 ORF71 41387 41866 ATG + 480 Hypothetical protein Acinetobacter phage  2E−110 100 YP_009055490.1 YMC-13-01-C62 ORF72 41876 42895 ATG + 1020 Hypothetical protein Acinetobacter phage 0 100 YP_009055489.1 YMC-13-01-C62 ORF73 42975 43313 ATG + 339 Hypothetical protein Acinetobacter phage 3E−21 43 ADO14384.1 AB1 ORF74 43313 43762 ATG + 450 Hypothetical protein Acinetobacter phage 1E−84 80 ADO14383.1 AB1 ORF75 43778 44053 ATG + 276 Hypothetical protein Acinetobacter phage 2E−58 98 YP 006383783.1 AP22 ORF76 44221 44445 ATG − 225 Hypothetical protein Acinetobacter phage 4E−47 100 AFV51493.1 IME-AB2

[0213] As shown in FIG. 22 and Table 12, the bacteriophage YMC16/01/R2016_ABA_BP contained linear dsDNA and was composed of 76 ORFs.

[0214] As a result of comparing the sequence of the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention with sequences of the existing bacteriophages, no bacteriophage having similarity to the bacteriophage according to the present invention was detected. From the above results, it can be seen that the bacteriophage YMC16/01/R2016_ABA_BP according to the present invention corresponds to a novel bacteriophage that has not been previously discovered.

[0215] Although the present invention has been described in detail above, the scope of the present invention is not limited thereto. It will be obvious to those skilled in the art that various modifications and changes can be made without departing from the technical spirit of the present invention described in the claims.

[0216] [Accession Number (1)]

[0217] Bacteriophage YMC14/01/P117_ABA_BP

[0218] Depositary institution name: Korean Culture Center of Microorganisms (Korea)

[0219] Accession number: KFCC11800P

[0220] Accession date: Nov. 15, 2018

[0221] [Accession Number (2)]

[0222] Bacteriophage YMC16/12/R4637_ABA_BP

[0223] Depositary institution name: Korean Culture Center of Microorganisms (Korea)

[0224] Accession number: KFCC11801P

[0225] Accession date: Nov. 15, 2018

[0226] [Accession Number (3)]

[0227] Bacteriophage YMC16/01/R2016_ABA_BP

[0228] Depositary institution name: Korean Culture Center of Microorganisms (Korea)

[0229] Accession number: KFCC11803P

[0230] Accession date: Nov. 15, 2018